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Binding and internalization of oxidized low-density lipoprotein (oxLDL) by immune 3 
cells within the arterial sub-intimal layer is a key step in the initiation and 4 
progression of atherosclerosis. Scavenger receptors (SRs) are a “super-family” 5 
of cell surface receptors expressed by immune cells which promote the removal 6 
of harmful non-self or altered-self targets, including oxidatively modified ligands 7 
such as oxLDL. Lectin-like oxidized LDL receptor-1 (LOX-1) is a member of the 8 
SR-E family of scavenger receptors. LOX-1 – oxLDL binding has been shown to 9 
exert significant pro-atherogenic effects. In this study, we used in vitro and in vivo 10 
models of atherosclerosis to explore the effectiveness of LOX-1 targeting in the 11 
inhibition of oxLDL binding and the amelioration of atherosclerosis and neointimal 12 
hyperplasia. LOX-1 was targeted using novel non-antibody artificial binding 13 
proteins, known as Affimers. Immunofluorescence studies using a tetracycline- 14 
inducible cell line expressing LOX-1 demonstrate the binding efficiency of 15 
fluorescent-labelled LOX-1 Affimers to LOX-1 in live cells. In same cell line, we 16 
co-incubated fluorescent-labelled oxLDL with increasing concentrations of LOX- 17 
1 Affimers. The findings show that LOX-1 Affimers inhibit LOX-1 – oxLDL binding. 18 
ELISA studies were carried out to identify LOX-1 affimers with comparable affinity 19 
for both human and murine LOX-1. The most cross-reactive LOX-1 Affimer was 20 
taken forward in to a transgenic mouse model of diet-induced atherosclerosis. 21 
This model used APO-E null and APO-E/LOX-1 null mice to compare the effects 22 
of LOX-1 knockout with LOX-1 targeting using LOX-1 affimers. LOX-1 knockout 23 
resulted in a reduction in aortic and peripheral arterial atherosclerosis, and 24 
neointimal hyperplasia. LOX-1 targeting with affimers produced promising 25 
results. Treatment with LOX-1 affimers reduced atherosclerosis and NIH, but to 26 
a lesser extent compared with LOX-1 knockout. Treatment with LOX-1 affimer 27 
exerted additional metabolic benefits including protective effects against diet- 28 
induced obesity and insulin resistance. The results from these studies suggest 29 
that LOX-1 is an attractive target in the development of novel therapeutics in 30 
atherosclerosis. Targeted LOX-1 inhibition potentially offers protective benefits in 31 
associated metabolic disorders such as obesity and insulin resistance.  32 
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CHAPTER 1  1 
INTRODUCTION 2 
 3 
1.1 Atherosclerosis and cardiovascular disease 4 
1.1.1 The national burden of cardiovascular disease 5 
Cardiovascular disease (CVD) is a widely-accepted umbrella term which includes 6 
coronary artery, cerebrovascular and peripheral artery disease. An international 7 
multicentre registry study of 67888 patients from 44 countries found that coronary 8 
artery disease (CAD) was the most prevalent of the three major disease states 9 
(Figure 1.1) (Bhatt et al., 2006). CVD is the leading cause of death worldwide, 10 
accounting for 30% of all deaths ('Global, regional, and national age-sex specific 11 
all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a 12 
systematic analysis for the Global Burden of Disease Study 2013,' 2015). In the 13 
United Kingdom, CVD accounts for a quarter of all deaths and costs the health 14 
service 9 billion pounds annually (    Cardiovascular disease statistics 2017., 15 
2017). It is the leading cause of death in women in the UK (28%) and the second 16 
most common cause of death in men (29%), behind cancer (32%). In England, 17 
prescriptions for the treatment of CVD increased six-fold between 1981 and 2013 18 
(Bhatnagar et al., 2015). The total number of operations and invasive procedures 19 
performed to treat CVD has risen steadily over the same time period (Bhatnagar 20 
et al., 2015). Large UK population studies have demonstrated that mortality rates 21 
from coronary artery and cerebrovascular disease have decreased significantly 22 
over the past 4 decades (Smolina et al., 2012; Lee, Shafe and Cowie, 2011). 23 
Improvements in mortality have been primarily attributed to risk factor 24 
modification, particularly smoking cessation and dietary changes (Unal, Critchley 25 
Julia and Capewell, 2004). 26 
Atherosclerosis is by far the leading pathophysiological process behind the 27 
development of CVD (Falk, 2006). Atherosclerosis is a systemic multifocal 28 
disease affecting medium and large sized arteries and is characterized 29 
macroscopically by the formation of plaque within the sub-intimal layer. Arterial 30 
 2 
thrombosis associated with atherosclerotic plaque manifests clinically as 1 







Figure 1.1. Prevalence of the three main clinical subtypes of cardiovascular 9 
disease. Coronary artery disease is the most prevalent, followed by 10 
cerebrovascular disease and peripheral artery disease. Figure adapted from 11 
Bhatt et al. (Bhatt et al., 2006). 12 
 13 
 3 
1.1.2 The pathophysiology of atherosclerosis 1 
 2 
1.1.2.1 Lesion initiation and progression 3 
Atherosclerosis is a complex, progressive, chronic inflammatory process 4 
characterized by the accumulation of lipid and fibrous elements within the arterial 5 
wall, manifesting macroscopically as atherosclerotic plaque (Figure 1.2). 6 
Abnormally high serum low-density lipoprotein (LDL) concentrations leads to the 7 
infiltration of LDL in to the subendothelial space, where it becomes chemically 8 
modified by oxidation due to free radicals produced by cellular respiration. The 9 
process of atherosclerosis is widely understood to be initiated by the abnormal 10 
accumulation of this oxidized low-density lipoprotein (oxLDL) within the sub- 11 
endothelial matrix (Lusis, 2000). An inflammatory cascade within the endothelium 12 
simultaneously leads to the production of adhesion molecules and chemotactic 13 
factors. Monocytes attach to the endothelium via the adhesion molecules and 14 
penetrate to the subendothelial space, where they differentiate and mature in to 15 
macrophages. The recruited macrophages bind and internalize oxLDL rapidly to 16 
form lipid-laden foam cells, promoting pro-atherosclerotic events i.e. 17 
atherogenesis (Gistera and Hansson, 2017). Vascular smooth muscle cells 18 
(VSMCs) within the blood vessel media layer are affected by growth factors being 19 
secreted by the endothelium in response to the accumulation of oxLDL 20 
(Katakami, 2018). VSMCs transform and migrate in to the intima and begin to 21 
actively produce extracellular matrix leading to sclerosis and intimal thickening. 22 
VSMCs also take up oxLDL and form foam cells, contributing to the formation of 23 
the atherosclerotic plaque (Katakami, 2018). 24 
In normal physiology, acute inflammation is followed by a resolution phase where 25 
tissue repair and restoration of homeostasis occurs (Nathan and Ding, 2010). In 26 
chronic inflammatory states where there is a persistent inflammatory stimulus, 27 
the resolution phase becomes defective due to the impaired synthesis and 28 
increased degradation of resolution mediators (Tabas and Lichtman, 2017). 29 
Atherosclerosis is such a chronic inflammatory process. Failure of the 30 
inflammatory process to resolve leads to an amplification cycle of ongoing 31 
inflammation and tissue injury, contributing to the clinical progression of plaque. 32 
The clinical consequences of atherosclerosis relate principally to acute thrombo- 33 
 4 
occlusive events at the site of plaque disease. Plaques become most dangerous 1 
in this regard when they exhibit features which increase the likelihood of rupture; 2 
such as large areas of necrosis and thinning of the overlying fibro-collagenous 3 
cap (Virmani et al., 2002). Plaque rupture exposes underlying thrombogenic 4 






Figure 1.2. Formation of the atherosclerotic plaque. Within the blood vessel 11 
intima, LDL accumulation leads to a chronic inflammatory process leading to the 12 
transmigration of immune cells and the formation of foam cells. EC; endothelial 13 
cell. ICAM; intercellular adhesion molecule -1. Inf; interferon- gamma. LDL; low- 14 
density lipoprotein. oxLDL; oxidized low-density lipoprotein. SR; scavenger 15 
receptor. Th-1; T-helper 1 cell. VCAM; vascular cell adhesion molecule -1. 16 
VSMC; vascular smooth muscle cell.  17 
 5 
1.1.2.2 The role of lipoprotein particles in atherosclerosis 1 
Anitschkow first reported the relationship between cholesterol and atherogenesis 2 
in 1913 by demonstrating the development of atheroma in oil-fed rabbits 3 
(Anitschkow, 1913). Later, large human epidemiological studies have confirmed 4 
the association between raised serum cholesterol and LDL-cholesterol and the 5 
risk of cardiovascular events (Stamler, Wentworth and Neaton, 1986; Castelli et 6 
al., 1986). Lipids such as cholesterol and triglycerides are essential components 7 
of the human diet, however they are insoluble in water and must be transported 8 
within the blood circulation bound to proteins; thus, the formation of lipoprotein 9 
particles. Lipoprotein particles are involved in the absorption and transport of 10 
dietary lipids from the small intestine to the liver, followed by peripheral tissues, 11 
and from the peripheral tissues back to the liver and intestine (reverse cholesterol 12 
transport). Lipoprotein particles are complex substances consisting of a central 13 
hydrophobic core of non-polar lipids, primarily cholesterol esters and 14 
triglycerides, which is surrounded by a hydrophilic membrane consisting of 15 
phospholipids, free cholesterol, and apolipoproteins (Figure 1.3). Lipoprotein 16 
particles can be subdivided into 7 classes based on their molecular weight, lipid 17 
composition and apolipoproteins (Figure 1.4). Of the seven classes of lipoprotein 18 
particles, LDL is widely considered to be the most pro-atherogenic owing to the 19 
following properties:  20 
• LDL particles have a reduced affinity to the LDL receptor (LDLR) and is 21 
therefore retained in the circulation for longer. 22 
• LDL particles enter the arterial wall more easily compared with larger 23 
lipoproteins. 24 
• LDL particles contain apolipoprotein-B100 (APO-B100), which binds avidly 25 
to intra-arterial proteoglycans leading to trapping within the arterial wall.  26 
• LDL particles are more susceptible to oxidative modification, with oxLDL 27 
being rapidly taken up by macrophages.	 28 
APO-B100 is the major structural component of very-low-density lipoprotein 29 
(VLDL), intermediate-density lipoprotein (IDL) and LDL. There is a single 30 
molecule of apo-B100 per VLDL, IDL or LDL particle. Ionic bonds between 31 
positively charged intra-arterial proteoglycans and negatively charged APO-B100 32 
lead to the retention of LDL within the arterial wall. Transgenic mouse studies 33 
 6 
have shown that single point mutations in APO-B100 impairs proteoglycan-LDL 1 
binding and reduces APO-B100 retention and atherosclerosis in the arterial wall, 2 
strengthening the hypothesis that the presence of APO-B100 and its interaction 3 
with proteoglycans is a key initiator in atherogenesis (Borén et al., 1998; Skalen 4 
et al., 2002). Retained LDL particles are susceptible to oxidative modification, 5 
forming oxLDL, due to structural changes in the APO-B100 molecule and lipid 6 
modification, brought about primarily by the interaction between LDL and 7 
proteoglycans.  8 
Several oxidases and peroxidases are known to oxidize LDL both in vitro and in 9 
vivo. Known agents include myeloperoxidase (MPO), xanthine oxidase, 10 
nicotinamide adenine dinucleotide phosphate oxidase, inducible nitric oxide 11 
synthase and lipoxygenases such as 5-lipoxygenase (5-LOX) and 12/15 12 
lipoxygenase (12/15-LOX) (Linton, Yancey and Davies, Jan 2019). Whilst the 13 
extent to which each agent is involved is not yet fully understood, we do know 14 
from transgenic mouse models and human studies that MPO and the 15 
lipoxygenases are pro-atherogenic and may be useful as biomarkers for 16 
cardiovascular disease states (Michowitz et al., 2008; Brennan et al., 2001; 17 
Dobrian et al., 2011). 18 
MPO and the lipoxygenases are the most closely linked to LDL oxidation. In vitro 19 
and ex vivo models have identified that the release of MPO is primarily from 20 
activated immune cells (primarily neutrophils) within the subintimal layer (Baldus 21 
et al., 2001).  The mechanisms behind the release of MPO from degranulating 22 
immune cells is not fully understood, however evidence suggests that reactive 23 
oxygen species (ROS) activity and the activation of Src and p38 mitogen 24 
activated protein kinase signaling pathways play important roles (Khan, Alsahli 25 
and Rahmani, 2018). 5-LOX and 12/15-LOX is expressed in vascular cells, such 26 
as endothelial cells and VSMCs, as well as in immune cells and adipose tissue 27 
(Dobrian et al., 2011). The stimulus for the release of lipoxygenase is also not 28 
fully understood, however similar to MPO, ROS activity is thought to play a role 29 
(Mashima and Okuyama, 2015). Whilst native LDL does not interact with immune 30 
cells, oxLDL does. Following oxidative modification, oxLDL is recognized by 31 
tissue macrophages, leading to (a) oxLDL uptake and the formation of foam cells, 32 







Figure 1.3. Structure of the low-density lipoprotein (LDL) particle. 6 
Lipoprotein particles consist primarily of a central hydrophobic core of non-polar 7 
lipids, largely cholesterol esters and triglycerides, which is surrounded by an 8 
amphipathic lipid monolayer consisting of phospholipids, free cholesterol, and 9 











Figure 1.4. Lipoprotein particle subdivision into classes. HDL particles are 4 
understood to be anti-atherogenic, whilst LDL, IDL and VLDL particles are pro- 5 
atherogenic. HDL; high-density lipoprotein. LDL; low density lipoprotein. LP(a); 6 
lipoprotein-a. IDL; intermediate-density lipoprotein. VLDL; very low-density 7 
lipoprotein. Figure adapted from Feingold et al. (Feingold and Grunfeld, 2018). 8 
 9 
1.1.2.3 Vascular oxidative stress 10 
Oxidative stress is known to play a role in atherogenesis, while endothelial nitric 11 
oxide (NO) production inhibits it. Reactive oxygen species (ROS) are oxygen- 12 
derived small molecules, including oxygen radicals, hydroxyl, peroxyl, alkoxyl and 13 
certain non-radicals that are either oxidizing agents and/or are easily converted 14 
into radicals, such as hypochlorous acid, ozone, singlet oxygen, and hydrogen 15 
peroxide (Bedard and Krause, 2007a). ROS avidly interact with a wide range of 16 
molecules such as proteins, lipids, carbohydrates, and nucleic acids. Through 17 
such interactions, ROS promotes the oxidative modification of molecules 18 
 9 
associated with atherosclerosis, most importantly LDL (Bedard and Krause, 1 
2007b). Regions of increased arterial wall shear stress and disturbed blood flow 2 
such as bifurcations and branches are associated with the greatest burden of 3 
atherosclerosis. Increased concentrations of ROS and reduced production of 4 
endothelial NO are understood to contribute significantly to this phenomenon 5 
(Forstermann, Xia and Li, 2017). 6 
Sources of increased ROS include the NOX family of NADPH oxidases, xanthine 7 
oxidase (XO), mitochondria, and uncoupled endothelial nitric oxide synthase 8 
(eNOS). Crosstalk between these pro-oxidant systems maintains a cycle of 9 
increasing ROS production (Forstermann, Xia and Li, 2017).  The primary 10 
function of NOX is the transmembrane transfer of electrons. The electrons are 11 
usually accepted by an oxygen molecule, leading to the reduction of oxygen to 12 
superoxide. There are 7 known isoforms of NOX, 4 of which are expressed in 13 
immune and vascular cells (NOX-1, NOX-2, NOX-4, NOX-5) (Bedard and 14 
Krause, 2007b). Not all isoforms are pro-atherogenic. NOX-1 and -2 have been 15 
shown to play a pro-atherogenic role in animal and human studies, while similar 16 
studies have found NOX-4 to be protective (Fulton and Barman, 2016). XO Is 17 
found both in the circulation and in vascular cells (White et al., 1996). XO 18 
expression is also increased in human atherosclerotic plaques and its activity is 19 
enhanced by vascular shear stress, suggesting a role for XO-derived superoxide 20 
molecules in atherosclerosis (Patetsios et al., 2001; McNally et al., 2003). 21 
Furthermore, XO inhibition in APO-E null mice leads to the attenuation of 22 
atherosclerosis (Nomura et al., 2014).  23 
eNOS promotes endothelial NO production under normal conditions, but 24 
becomes dysfunctional under oxidative stress. NO undergoes rapid oxidative 25 
deactivation under oxidative stress, leading to endothelial cell dysfunction. 26 
Ongoing endothelial oxidative stress renders eNOS “uncoupled”, whereby 27 
oxygen reduction in the synthesis of NO is uncoupled from the reaction and 28 
preferentially produces superoxide, at the expense of NO production 29 
(Forstermann, Xia and Li, 2017). This mechanism has been found in association 30 
with atherosclerosis in transgenic mouse models of atherosclerosis and human 31 
studies (Wohlfart et al., 2008; Xia et al., 2010; Antoniades et al., 2007). Under 32 
normal conditions, mitochondria generate a physiological amount of superoxide. 33 
 10 
Mitochondrial oxidative stress results from excessive ROS production or 1 
insufficient ROS detoxification in the cytoplasm. Mitochondrial oxidative stress 2 
has been found in association with human atherosclerotic plaque and to exert a 3 
pro-atherogenic effect in transgenic knockout studies (Corral-Debrinski et al., 4 
1992; Ballinger et al., 2002).  5 
 6 
1.1.2.4 The inflammatory component of atherosclerosis 7 
Atherosclerosis is a chronic inflammatory process. Inflammation is initiated by 8 
exposure of the endothelium to noxious stimuli such as dyslipidaemia / oxLDL 9 
(Raggi et al., 2018). Endothelial cells respond by upregulating the transcriptional 10 
messenger protein “nuclear factor kappa-light-chain-enhancer of activated B 11 
cells” (NFkB) and releasing a series of substances that enhance leukocyte 12 
adhesion including E-selectin and vascular and inter-cellular adhesion molecules 13 
(VCAM-1 and ICAM-1) (Raggi et al., 2018). Circulating leucocytes thus adhere to 14 
the endothelium and migrate to the sub-intimal space, where along with resident 15 
tissue macrophages, begin to engulf oxLDL particles. Non-classical patrolling 16 
monocytes also engulf oxLDL early in atherogenesis through the expression of 17 
scavenger receptor (SR) CD36 (Marcovecchio et al., 2017). The initial immune 18 
cell activity generates more adhesion molecules, promoting the recruitment of 19 
bone marrow-derived monocytes from the circulation to the intima. Once within 20 
the intimal layer, monocytes differentiate to macrophages and engulf oxLDL, 21 
leading to the formation of foam cells (Raggi et al., 2018). 22 
The presence of cytoplasmic cholesterol crystals within foam cells and the 23 
subsequent activation of SRs leads to the release of activated cytokines 24 
interleukin-1A (IL-1A), interleukin-1B (IL-1B) and interleukin-18 (IL-18) in to the 25 
extracellular space (Sheedy et al., 2013). Interactions between cytokines and 26 
their receptors result in the release of ROS and matrix degrading enzymes, and 27 
the activation and proliferation of pro-atherogenic T-helper 1 (Th1) cells. It is 28 
worth noting that not all T-helper cells are pro-atherogenic. For example, 29 
regulatory T-lymphocytes and T-helper 17 cells act to stem atherosclerosis by 30 
secreting transforming growth factor-beta / IL-10 and IL-17 respectively (Libby, 31 
Ridker and Hansson, 2009; Gistera et al., 2013). 32 
 11 
VSMCs contribute to the inflammatory process and do form foam cells, albeit to 1 
a lesser degree than the primary immune cells. The activation of VSMCs in 2 
response to the exposure to oxLDL, cytokines and growth factors leads to a 3 
phenotypic transition from a contractile, non-proliferative phenotype to a 4 
“macrophage-like” phenotype with proliferating, migratory and matrix-secreting 5 
properties, as well as the ability to express cell-surface macrophage markers and 6 
develop phagocytic activity (Raggi et al., 2018). 7 
 8 
1.1.2.5. Apoptosis, necroptosis and defective efferocytosis 9 
Macrophages undergo endoplasmic reticulum (ER) stress, apoptosis and 10 
necroptosis due to the uptake of toxic non-esterified cholesterol within oxLDL 11 
(Raggi et al., 2018). Apoptosis results from the activation of the unfolded-protein 12 
response (UPR) within the ER following exposure to cholesterol (Rayner, 2017). 13 
The resulting ER stress stimulates the production of CCAAT enhancer- binding 14 
protein homologous protein (CHOP) and initiates the release of Ca2+ from the 15 
ER, release of cytochrome C from the mitochondria and activation of caspase- 16 
dependent apoptosis (Gonzalez and Trigatti, 2017). Early in atherogenesis, 17 
apoptosis is protective as it allows the clearance of lipid-engorged cells and 18 
reduced lesion cellularity. Efferocytosis (the phagocytosis and clearance of 19 
apoptotic cells) is initially efficient, but becomes defective leading to the 20 
accumulation of dead foam cells and apoptotic debris within the lesion. 21 
Secondary necrosis of apoptotic cells occurs, causing rupture and release of 22 
toxins(Raggi et al., 2018). Impairment of MerTK activity (macrophage cell surface 23 
receptor primarily responsible for efferocytosis) may have a role in the failure of 24 
efferocytosis, but the exact mechanism remains unclear (Kojima, Weissman and 25 
Leeper, 2017). 26 
Necroptosis is an alternative form of programmed cell death observed in 27 
macrophages after prolonged exposure to oxLDL (Karunakaran et al., 2016). 28 
Necroptosis unlike apoptosis, stimulates an innate inflammatory response due to 29 
the unregulated release of intracellular compounds. Necroptotic cells feature 30 
more predominantly in advanced atherosclerotic lesions, particularly those with a 31 
necrotic core. Defective efferocytosis of necroptotic cells gives rise to more 32 
 12 
inflammation and the expansion of the necrotic core rendering the lesion more 1 
prone to rupture. 2 
 3 
1.1.3 Neointimal hyperplasia 4 
 5 
1.1.3.1 Clinical perspective of NIH 6 
Minimally invasive and surgical treatment modalities for symptomatic 7 
cardiovascular disease generally aim to restore blood flow to areas of ischaemia 8 
by recanalising stenotic or occluded arteries. The techniques used in current 9 
practice include angioplasty, stenting, surgical endarterectomy and surgical 10 
bypass. Advances in such interventions have greatly improved clinical outcomes 11 
for our patients, however their long-term durability is an area of concern. Vessel 12 
re-stenosis and / or occlusion is clinically more challenging compared with native 13 
vessel disease and the outcomes of re-intervention are less promising. The main 14 
pathological process underlying re-stenosis related to vascular intervention is 15 
neointimal hyperplasia (NIH).  16 
 17 
1.1.3.2 Pathology of NIH 18 
NIH is a complex inflammatory process defined by thickening of the intimal layer 19 
due to the proliferation of VSMCs and the production of extra-cellular matrix 20 
(Kijani et al., 2017). Intimal thickening leads to luminal narrowing, restenosis and 21 
potentially arterial / graft occlusion. NIH is initiated by endothelial denudation and 22 
the accumulation and activation of platelets (McMonagle, 2020). Endothelial cell 23 
and platelet activation leads to the release of growth factors such as platelet- 24 
derived growth factor and fibroblast growth factor-2, which stimulates VSMC to 25 
proliferate and migrate from the tunica media to the tunica intima (McMonagle, 26 
2020). Additionally, VSMCs undergo a phenotypic change from their normal 27 
contractile function to a secretory one, leading to the production and deposition 28 
of extracellular matrix in the neointima (Jain et al., 2020). Oxidative stress and 29 
downstream inflammatory signaling in the injured artery leads to ongoing 30 
migration and proliferation, and lesion progression (Li et al., 2018a). 31 
 32 
 13 
1.2 Scavenger Receptors 1 
1.2.1 Background 2 
Goldstein and co-workers first described scavenger receptors (SRs) in 1979 3 
whilst investigating the involvement of LDL in the formation of foam cells in 4 
atherosclerosis (Goldstein et al., 1979; Brown et al., 1980). The authors found 5 
that macrophages exhibited high affinity binding sites recognizing negatively 6 
charged modified LDL, resulting in rapid internalization and the formation of foam 7 
cells (Brown et al., 1980). SRs are defined as cell surface receptors which 8 
typically bind multiple ligands and promote the removal of harmful non-self or 9 
altered-self targets. They often function by mechanisms that include endocytosis, 10 
phagocytosis, adhesion, and signaling that ultimately lead to the elimination of 11 
degraded or harmful substances (Prabhudas et al., 2014). They share the ability 12 
to recognize common ligands including lipoproteins, phospholipids, apoptotic 13 
cells, carbohydrates and cholesterol ester, however the primary amino acid 14 
sequences of proteins within each class bear little or no resemblance (Zani et al., 15 
2015). 16 
Most SRs are primarily expressed in immune cells, particularly macrophages 17 
under conditions of oxidative stress, commonly in association with 18 
atherosclerosis. Expression of SRs has been identified in other cell types and 19 
processes contributing to a wide range of diseases such as degenerative brain 20 
disease (Wilkinson and El Khoury, 2012; Singh et al., 2010), malignancy (Bachli 21 
et al., 2006) and systemic inflammatory states such as sepsis (Leelahavanichkul 22 
et al., 2012), rheumatoid arthritis (Matsushita et al., 2002), and renal vasculitis 23 
(Nagai et al., 2016). 24 
 25 
  26 
 14 
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 1 
1.2.2 Targeting SRs in cardiovascular disease 2 
SRs are multi-ligand receptors, each class with a unique structure, but all 3 
receptors sharing a common function; the scavenging of harmful substances. 4 
Many SRs are expressed in cells involved in the development of atherosclerosis 5 
which is the main contributor to cardiovascular disease. Research to date has 6 
identified the main players: SR-A; CD36; lectin-like oxidized LDL receptor-1 7 
(LOX-1); CXCL16; Receptor for advanced glycation end-products (RAGE). Each 8 
of receptor shows promise in future applications as biomarkers for disease and 9 
novel therapeutics. The applications of SR-A, CD36, CXCL16 and RAGE are 10 
discussed here. LOX-1 is the primary focus of this research and will be discussed 11 
in more detail, separately. 12 
 13 
1.2.3 SRs as Biomarkers 14 
SRs have been identified as having potential roles in genetic screening or as 15 
diagnostic and prognostic biomarkers in cardiovascular disease. Screening for 16 
patients with a genetic predisposition to cardiovascular disease has potentially 17 
far reaching benefits in disease prevention and early management. 18 
Polymorphisms in genes encoding both CD36 have been associated with 19 
 17 
increased overall cardiovascular risk (Che, Shao and Li, 2014; Jayewardene et 1 
al., 2014; Morini et al., 2016). Cohort studies of both healthy and known coronary 2 
artery disease patients have shown an association between CD36 genotype and 3 
increased lipid oxidation, overall cardiovascular risk and specifically the 4 
development of premature coronary artery disease (Che, Shao and Li, 2014; 5 
Jayewardene et al., 2014). 6 
Much has been done to investigate the diagnostic value of quantifying SR levels 7 
in acute coronary syndrome. Both serum concentrations of soluble protein and 8 
levels of protein expression in immune cells have been studied. Using an “SR-A 9 
index” which quantifies monocyte SR-A expression in peripheral blood smears 10 
from patients with coronary artery disease, investigations demonstrate that an 11 
increase in SR-A index is associated with atherosclerotic plaque complications 12 
(disruption, fissure, erosion) (Nakayama et al., 2008). Furthermore the SR-A 13 
index may be useful in determining plaque morphology which in turn may help 14 
guide therapy in coronary artery disease (Emura et al., 2011; Emura et al., 2007). 15 
Similar studies have shown an association between circulating monocyte CD36 16 
expression and atheroma burden in coronary artery disease patients (Teupser et 17 
al., 2008). Promising results from a study using CD36 specific nanovesicles in 18 
detecting and quantifying atherosclerosis in LDLR-null mice indicate their 19 
potential application as a tool in non-invasive imaging of atherosclerosis (Nie et 20 
al., 2015). 21 
CXCL16 acts both as a scavenger receptor which binds oxLDL and as an 22 
inflammatory chemokine, establishing it as a molecule of interest in 23 
atherosclerosis (Aslanian Ara and Charo Israel, 2006). Serum soluble CXCL16 24 
has been evaluated as a potential biomarker in carotid artery disease, coronary 25 
artery disease and inflammatory cardiomyopathy. In 118 patient presenting with 26 
an acute ischaemic stroke, serum CXCL16 concentrations were significantly 27 
higher in those with vulnerable carotid plaque, a higher degree of luminal stenosis 28 
and increased intima-media thickness (Jin, 2017). A number of small clinical 29 
studies have also shown that measuring serum CXCL16 concentration can 30 
improve diagnostic accuracy when combined with troponins and soluble LOX-1 31 
in acute coronary syndrome, and that it may be of particular benefit in those with 32 
type 2 diabetes (Mitsuoka et al., 2009; Zhou et al., 2016). As a prognostic 33 
 18 
biomarker, a study of 1351 patients presenting with acute coronary syndrome 1 
found that a single measurement of raised serum CXCL16 within 24 hours of 2 
admission to hospital was associated with higher long term mortality, owing 3 
presumably to its role in promoting a pro-atherogenic inflammatory response 4 
(Jansson et al., 2009). CXCL16 has also been proposed as a prognostic 5 
biomarker in inflammatory cardiomyopathy and heart failure. In 174 patients with 6 
heart failure, myocardial biopsy samples stained for CXCL16 showed significantly 7 
enhanced expression in inflammatory cardiomyopathy compared with non- 8 
inflammatory cardiomyopathy (Borst et al., 2014). The same study found that 9 
increased CXCL16 expression was an independent predictor of death in both 10 
inflammatory and non-inflammatory cardiomyopathy patients. 11 
Like other SRs, RAGE undergoes proteolytic cleavage to form a circulating 12 
soluble form (sRAGE). sRAGE has been proposed as a novel diagnostic and 13 
prognostic biomarker for cardiovascular disease particularly in patients with 14 
diabetes mellitus. Multiple cohort studies have found that an increasing serum 15 
concentration of sRAGE is predictive for coronary artery disease and future 16 
cardiovascular events (Nakamura et al., 2007; Nin et al., 2010; Colhoun et al., 17 
2011; Fujisawa et al., 2013). The relationship is not entirely straightforward, 18 
evidenced by a study of sRAGE levels in 127 consecutive patients with non-acute 19 
coronary artery disease (Basta et al., 2012). Using computed tomography 20 
angiography, the authors found that higher concentrations of sRAGE were 21 
inversely related to overall plaque burden. A study of 328 non-diabetic males 22 
found the same inverse relationship (Falcone et al., 2005). Certainly to-date it 23 
appears that sRAGE has a potential future role as a biomarker in patients with 24 
diabetes mellitus, however its utility in non-diabetic patients is probably less 25 
promising.  26 
 27 
1.2.4 Therapeutic strategies in atherosclerosis 28 
 29 
1.2.4.1 Clinically approved treatments 30 
HMG Co-A reductase inhibitors, otherwise known as statins, are widely utilised 31 
cholesterol-lowering agents used in the treatment and prevention of 32 
 19 
cardiovascular disease (Hawkes, 2017). Statins not only reduce total serum 1 
cholesterol , but also exhibit pleotropic effects on the vessel wall including 2 
improved endothelial function, a reduction in vascular inflammation and 3 
enhanced plaque stability (Liao, 2002). The effect of statin therapy on scavenger 4 
receptor function is not yet understood. An in vitro study of atorvastatin therapy 5 
in oxLDL exposed immortalized human monocytes (THP-1 cells) found that 6 
atorvastatin attenuated SR-A expression and monocyte chemoattractant protein- 7 
1 in a dose-dependent manner (Zhu et al., 2007). Atorvastatin therapy also 8 
reduced overall foam cell formation, indicating a possible association between 9 
cholesterol levels and plaque formation. Using cultured murine and human 10 
macrophages, incubation with pitavastatin was associated with significantly 11 
increased expression of SR-B1: this expression is known to be protective against 12 
atherogenesis (Han et al., 2004; Arai et al., 1999). Statins also increase 13 
production of endothelium-protective nitric oxide in-vitro in a rapid, dose 14 
dependent manner via the activation of SR-B1 (Arai et al., 1999). 15 
Statin therapy may also interact with the pro-atherogenic SR RAGE. RAGE 16 
expression is down-regulated in atherosclerotic plaques from diabetic patients 17 
treated with simvastatin (Cuccurullo et al., 2006). Atorvatstatin was also found to 18 
increase the production of sRAGE in vitro. The soluble isoforms of RAGE are 19 
thought to act as a decoy and inhibit the pro-atherogenic effects of advanced 20 
glycation endproducts (Santilli et al., 2007). Whilst the results of this study are 21 
convincing, it does raise the issue of the range of actions of structurally different 22 
statins on SR activity. While the mentioned effects were seen with atorvastatin 23 
therapy, the same effects were not detected when pravastatin was used.  24 
Monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) 25 
inhibtors are relatively novel LDL-lowering agents which have recently been 26 
approved for clinical use. PCSK9 is a protease required for the degradation of 27 
the LDL-receptor (LDLR) (Wang and Liu, 2019). PCSK9 inhibitors work by 28 
inhibiting PCSK9-LDLR interaction leading to decreased LDLR degradation and 29 
ultimately a reduction in serum LDL-cholesterol. Studies by Ding et al 30 
investigating the possibility of interactions between PCSK9 and LOX-1 suggest 31 
that cross-talk between PCSK9 and LOX-1 exists in the form of positive feedback 32 
(Ding et al., 2015). The authors demonstrate LOX-1 ablation in cellular and 33 
 20 
transgenic mouse experiments results in reduced PCSK9 expression and vice 1 
versa with PCSK9 ablation. The effects of monoclonal PCSK9 inhibitors on LOX- 2 
1 expression in humans is not known, however it is conceivable that LOX-1 3 
downregulation as a result of PCSK9 inhibition could be providing additional anti- 4 
atherogenic benefit. 5 
Peroxisome proliferator-activated receptor-γ (PPAR-γ) exhibits anti-inflammatory 6 
and anti-diabetic properties. Pioglitazone is a PPAR-γ agonist which is commonly 7 
prescribed as a glucose-lowering agent in type 2 diabetes mellitus (T2DM). 8 
Human and animal studies have described the effect of pioglitazone on SR 9 
expression and function in the context of diabetes and metabolic syndrome. In a 10 
study of 30 patients with polycystic ovarian syndrome (PCOS) combined with 11 
either increased fasting glucose or obesity, the concentration of serum soluble 12 
CD36 was significantly raised compared to  healthy controls (n=14) (Glintborg et 13 
al., 2008). Further, it was found that treatment with pioglitazone significantly 14 
reduced the concentrations of soluble CD36 and the inflammatory marker C- 15 
reactive protein while improving insulin sensitivity. The authors conclude that the 16 
evidence strengthens the basis for an association between sCD36 and insulin 17 
resistance in PCOS. Pioglitazone may in addition have potential in reducing 18 
overall cardiovascular risk in this cohort. A further study investigates the effects 19 
of pioglitazone on atherosclerosis in diabetic APO-E null mice and found that 20 
atherosclerosis was attenuated via RAGE signaling pathways (Gao et al., 2017). 21 
The authors demonstrated that pioglitazone administration reduced 22 
atherosclerotic load in harvested aortae, inhibited RAGE expression in harvested 23 
tissues and in cultured murine vascular smooth muscle cells. 24 
 25 
1.2.4.2 Herbal and traditional medicine therapies 26 
Herbal and traditional medicines have attracted some interest in scavenger 27 
receptor research relating to atherosclerosis. Ginkgo biloba root is used in 28 
traditional Chinese medicine for a variety of illnesses. Its extract and its 29 
biologically active molecules “ginkgolides” have demonstrated anti-oxidant and 30 
anti-inflammatory properties when applied to endothelial cells (Tsai et al., 2010). 31 
SR-A expression and oxLDL uptake was significantly reduced in the presence of 32 
Ginkgo biloba extract in vitro, and moreover SR-A expression and aortic 33 
 21 
atherosclerotic load was significantly reduced in APO-E null mice treated with 1 
Ginkgo biloba extract (Tsai et al., 2010). Similar results have been obtained in rat 2 
models demonstrating a significant reduction in circulating inflammatory factors 3 
and aortic SR-A expression compared with controls (Zhu et al., 2016). 4 
Lowbush blueberries have been shown to reduce atherosclerosis in APO-E null 5 
mice (Xie et al., 2011). The mechanisms for this effect are not yet fully 6 
understood, however the effects on SR-A and CD36 expression has been 7 
evaluated. Investigators found that APO-E null mice fed diet containing 1% 8 
lowbush blueberry had significantly reduced expression of SR-A and CD36 and 9 
significantly reduced foam cell formation (Xie et al., 2011).  10 
 11 
1.2.4.3 Novel therapeutics 12 
Transgenic mouse studies have demonstrated that SR-A deletion leads to a 13 
significant reduction in aortic atherosclerotic load, leading to numerous studies 14 
aiming to identify novel therapeutics based on SR-A inhibition (Babaev et al., 15 
2000). Amphiphilic macromolecules (AM) selected for SR-A binding affinity have 16 
shown promising results in atherosclerosis attenuation (Hehir et al., 2012; Iverson 17 
et al., 2011). SR-A specific AMs reduced both oxLDL uptake in SR-A expressing 18 
human embryonic kidney cells and pro-inflammatory signaling in activated THP- 19 
1 macrophages (Iverson et al., 2011). The authors also demonstrated a reduction 20 
in intimal cholesterol accumulation and macrophage retention post carotid artery 21 
injury in rats fed a high fat diet. 22 
Higher serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) has 23 
been associated with superior outcomes in patients with acute coronary 24 
syndromes, however the mechanisms at the time were not fully understood 25 
(Fichtlscherer et al., 2004; Anguera et al., 2002). It has since been shown that 26 
incubation with IL-10 reduces oxLDL uptake and SR-A expression in activated 27 
THP-1 macrophages, providing further support for IL-10 as a potential treatment 28 
in atherosclerosis, particularly acute coronary syndrome (Yang et al., 2011). 29 
SR-A expression in macrophages is also reduced leading to attenuation of 30 
atherosclerosis in APO-E null mice by intermedin; a novel member of the 31 
calcitonin gene-related peptide family (Dai et al., 2012). Intermedin has been 32 
 22 
previously implicated in the maintenance of vascular homeostasis and has been 1 
shown to contribute to the reduction of calcium deposition in atherosclerotic 2 
plaque (Cai et al., 2009). The authors found that levels and stability of 3 
phosphatase and tensin homolog (PTEN) were associated with reduced SR-A 4 
expression leading to the conclusion that intermedin attenuates atherosclerosis 5 
via PTEN mediated SR-A inhibition and this has potential in the treatment of 6 
atherosclerotic disease. SR-A has also been identified as a potential target in 7 
diabetic nephropathy, although no agent has been identified thus far. In SR-A null 8 
mice with streptozotocin-induced diabetes mellitus, there is a significant reduction 9 
in markers of nephropathy including albuminuria, glomerular hypertrophy, 10 
mesangial matrix expansion, parenchymal macrophage infiltration and 11 
overexpression of transforming growth factor-b compared with SR-A+/+ controls 12 
(Usui et al., 2007).  13 
The use of RNA interference mediated silencing to downregulate SR-A and CD36 14 
is effective in reducing oxLDL uptake in vitro and atherosclerotic load in vivo when 15 
one receptor is targeted alone, however interestingly when both receptors are 16 
targeted, there is no change observed against controls (Mäkinen et al., 2010). 17 
The authors also found that the downregulation of either SR-A or CD36 resulted 18 
in a reciprocal upregulation of the other. Crosstalk between two scavenger 19 
receptors may explain why the inhibition of multiple receptors could be less 20 
effective than inhibiting a single receptor. The results from studies of both SR-A 21 
and CD36 in tandem do conflict. Monoclonal antibody mediated inhibition of 22 
either SR-A or CD36 reduces foam cell formation in vitro; however, the authors 23 
did not block both receptors simultaneously (Seizer et al., 2010). Double 24 
knockout of SR-A and CD36 in APO-E null mice did not reduce aortic root 25 
atherosclerosis compared with APO-E null mice, however the authors did not 26 
study SR-A or CD36 knockout in isolation (Manning-Tobin et al., 2009). Isolated 27 
and double knockout has been studied by a different group, who found that CD36 28 
knockout significantly reduced aortic atherosclerotic load compared with controls, 29 
however SR-A knockout was less effective in isolation, and double knockout was 30 
similar in efficacy to CD36 knockout alone (Kuchibhotla et al., 2008). 31 
CD36 is a multi-ligand and multifunctional scavenger receptor which plays a 32 
complex role in cardio- and cerebrovascular disease states (Cho and Kim, 2009). 33 
 23 
It has been shown to exhibit both pro-atherogenic and anti-angiogenic properties 1 
both in vitro and in vivo (Cho, 2012; Mwaikambo et al., 2008). Investigators 2 
studying CD36 in cerebrovascular disease have demonstrated that CD36 null 3 
mice benefit from significantly improved angiogenesis after acute stroke (Qin et 4 
al., 2011). The same group have found that treatment with a cell-permeable 5 
antioxidant peptide (SS31) reduces cerebral oxidative stress and infarct size in 6 
mice subjected to transient middle cerebral artery occlusion (Cho et al., 2007). 7 
The effect was not seen in CD36 null controls, leading the authors to conclude 8 
that SS31 is producing the desired effects via CD36. 9 
Nanoparticles such as AMs and nanovesicles have been identified which bind to 10 
CD36 and inhibit oxLDL uptake in vitro (Chnari et al., 2006; Nie et al., 2015). 11 
CD36-targeted liposome-like nanovesicles show impressive binding affinities to 12 
CD36 in vitro and in vivo in atherosclerotic LDLR null mice. Atherosclerosis 13 
attenuation was not studied here, however the therapeutic potential of CD36- 14 
targeted nanovesicles is clear, given the results previously discussed from 15 
transgenic models studying the effects of CD36 knockout on atherosclerotic load. 16 
Synthetic proteins such as EP 80317; a CD36 selective ligand have been shown 17 
to reduce macrophage oxLDL uptake and atherosclerotic load in APO-E null mice 18 
(Marleau et al., 2005). Furthermore, investigators have demonstrated that 19 
treatment with this protein promotes reverse transport of cholesterol in 20 
macrophages and increases the excretion of cholesterol in faeces via the 21 
modulation of various receptors in the gut (LXRa, NPC1L1) (Bujold et al., 2013). 22 
The relationship between CXCL16 and atherogenesis is not as well established 23 
compared with SR-A, CD36 and LOX-1. As previously discussed, a soluble 24 
CXCL16 isoform has been identified as a potential novel biomarker in coronary 25 
artery disease. It has been shown that CXCL16 is highly expressed in human 26 
carotid and coronary artery atheroma (Minami et al., 2001). Hofnagel et al. have 27 
investigated the role of CXCL16 in atherosclerosis and found that CXCL16 was 28 
expressed primarily in endothelium at sites predisposed to atherosclerosis in 29 
harvested rabbit aorta (Hofnagel et al., 2011). The authors treated human 30 
umbilical vein endothelial cells with anti-CXCL16 antibody and demonstrated a 31 
significant reduction in monocyte adhesion. To date the efficacy of anti-CXCL16 32 
monoclonal antibody in animal model of atherosclerosis is untested. Interestingly 33 
 24 
a transgenic mouse found that LDLR/CXCL16 double null were more 1 
atherosclerotic compared with LDLR null alone (Aslanian and Charo, 2006). This 2 
is not the first time that knockout of a SR gene has produced contradictory results. 3 
As previously discussed, double knockout of SR-A/CD36 had no effect on the 4 
formation of atherosclerosis in APO-E null mice, while knockout of each gene in 5 
isolation reduced atherosclerosis compared with controls (Manning-Tobin et al., 6 
2009; Kuchibhotla et al., 2008). In contrast, the CXCL16 null mice are single SR 7 
knockout and it therefore remains that the role of CXCL16 in atherogenesis and 8 
its potential in therapeutics is less clear.  9 
Advanced glycation end-products (AGEs) are understood to be pro-atherogenic 10 
and are of interest in vascular disease associated with diabetes mellitus. 11 
Therapeutics aimed at the inhibition of advanced glycation with agents such as 12 
aminoguanidine-HCl, which inhibits crosslinking necessary to form AGEs has 13 
produced a range of beneficial cardiovascular effects in vivo (Bierhaus et al., 14 
1998). RAGE recognizes and internalizes oxLDL; RAGE expression is 15 
upregulated when exposed to AGEs which leads to an increase in oxLDL 16 
accumulation in vitro (Xu et al., 2016). The authors found that anti-RAGE 17 
antibody reversed this effect. A study investigating the role of RAGE in 18 
cardiovascular disease associated with obstructive sleep apnoea found that 19 
RAGE-targeted RNAi therapy reduced monocyte adhesion in HUVECs (Zhou et 20 
al., 2018). In vivo, diabetic APO-E/RAGE double null mice had a statistically non- 21 
significant reduction in aortic atherosclerotic load and reduced leucocyte 22 
adhesion and expression of pro-inflammatory mediators (Soro-Paavonen et al., 23 
2008). Interestingly, recombinant sRAGE administration in diabetic APO-E null 24 
mice suppressed aortic atherosclerosis while having no effect on plasma lipid 25 
profile or serum glucose concentration (Park et al., 1998). Immunohistochemical 26 
analysis of aortic atherosclerotic plaque showed reduced AGE and RAGE levels 27 
in mice treated with sRAGE, leading the authors to hypothesize that sRAGE acts 28 
as a “sponge” for AGEs thus reducing the expression of RAGE in vascular tissue, 29 




1.3 Structure and function of the LOX-1 SR 1 
1.3.1 Genetics and expression of LOX-1 2 
LOX-1 is a member of the SR-E family of scavenger receptors first described by 3 
Sawamura and co-workers in 1997 (Sawamura et al., 1997). With the premise 4 
that vascular endothelial cells both in vitro and in vivo internalize and degrade 5 
oxLDL via a receptor pathway unrelated to macrophage scavenger receptors, 6 
LOX-1 was cloned from bovine endothelial cells using expression cloning. LOX- 7 
1 is encoded by the oxidized LDL receptor 1 (OLR1) gene locus located within of 8 
the short arm of human chromosome 12 which is also enriched with genes 9 
involved in innate immunity (Yamanaka et al., 1998). LOX-1 is predominantly 10 
expressed in endothelial cells, but subsequently been detected in macrophages, 11 
smooth muscle cells and platelets (Yoshida et al., 1998a; Draude, Hrboticky and 12 
Lorenz, 1999; Chen et al., 2001b). Furthermore, LOX-1 is over-expressed in 13 
human and animal atherosclerotic lesions in vivo (Kataoka et al., 1999). 14 
Expression of LOX-1 is induced by a number of stimuli including oxLDL, 15 
angiotensin 2, shear stress and tumour necrosis factor a (Li et al., 1999; Murase 16 
et al., 1998; Kume et al., 1998). 17 
 18 
1.3.2 Structure of LOX-1 19 
LOX-1 is a type II integral membrane glycoprotein with a short N-terminal 20 
cytoplasmic domain, a single transmembrane domain, a short neck region and 21 
an extracellular C-type lectin-like fold (Figure 1.5). This C-type lectin-like fold is 22 
critically required for LOX-1 binding activity and is highly conserved within LOX- 23 
1 mammalian orthologues, notably at six cysteine residues which underpin the 24 
lectin-like fold by forming three intramolecular disulfide bonds (Shi et al., 2001). 25 
N-glycosylation of LOX-1 regulates protein folding within the endoplasmic 26 
reticulum, secretory transport to the plasma membrane and ligand recognition 27 
(Kataoka et al., 2000). It is likely that LOX-1 improves the efficiency of oxLDL 28 
binding by undergoing multimerization via inter-chain disulphide bonds between 29 
cysteine140 (Cys140) residues (Ishigaki et al., 2007) (Figure 1.6).  30 
 31 
 26 
1.3.3 LOX-1-mediated signal transduction 1 
The cellular effect of oxLDL is mainly dependent on specific binding to LOX-1, 2 
hence multiple signal transduction pathways involved in the development of 3 
atherosclerosis are affected by LOX-1 activation (Xu et al., 2013). When oxLDL 4 
binds to LOX-1, it induces rapid RhoA and Rac1 activation via MT1-MMP, which 5 
results in NADPH oxidase activation and eNOS downregulation (Sugimoto et al., 6 
2009). The resulting imbalance of NO and oxidative stress likely leads to 7 
endothelial cell dysfunction. The following pathways have also been implicated 8 
in the activation of LOX-1: p38 mitogen-activated protein kinase C (MAPK), 9 
p44/42MAPK, protein kinase C, protein kinase B, extracellular signal-regulated 10 
kinases 1/2 (ERK1/2), protein tyrosine kinase (Ogura et al., 2009).  11 
Adhesion molecules and chemokines such as E- and P- selectins, ICAM-1, 12 
VCAM-1 which mediate monocyte adhesion to endothelial cells, are 13 
overexpressed following LOX-1-mediated NF-κB activation by oxLDL (Ogura et 14 
al., 2009). Reactive oxygen species generated by LOX-1-oxLDL binding in the 15 
endothelial cell activate NF-Κb (Cominacini et al., 2000). NF-κB activation can 16 
induce upregulation of pro-inflammatory mediators as well as LOX-1 itself which 17 
in turn increase LOX-1-mediated oxLDL uptake, thus amplifying the effects of 18 
atherogenic oxLDL (Nagase et al., 1998). Additionally, LOX-1 activation changes 19 
endothelial cells and smooth muscle cells prone to apoptosis by increasing the 20 
B-cell lymphoma – 2 (Bcl-2) -associated X protein (Bax)/Bcl-2 ratio (Kataoka et 21 





Figure 1.5. Structure of human (A) and mouse (B) LOX-1. The molecule exists 3 
as a homodimer and has four domains: an extracellular C-terminal C-type lectin 4 
domain, a connecting neck domain, a single transcellular domain and a short N- 5 
terminal cytoplasmic tail. A disulphide bond exists between cysteine 140 in each 6 
of the C-type lectin domains. The C-type lectin domain sequence is highly 7 
conserved in mammals. Mouse LOX-1 is structurally similar, but contains triple 8 




Figure 1.6. LOX-1 binding to LDL. It is likely that LOX-1 improves the efficiency 3 
of oxLDL binding by undergoing multimerization via inter-chain disulphide bonds 4 
between Cys140 residues.  5 
 6 
1.4 LOX-1 in the pathology of cardiovascular disease 7 
1.4.1 Endothelial dysfunction 8 
Activation of LOX-1 by oxLDL results in endothelial activation and dysfunction, 9 
characterized by reduced endothelium-dependent relaxation, increased 10 
monocyte adhesion to endothelial cells, as well as endothelial cell apoptosis (Xu 11 
 29 
et al., 2013). OxLDL-LOX-1 binding activates arginase II leading to down- 1 
regulated nitric oxide production in endothelial cells, a main contributor to 2 
vascular relaxation (Ryoo et al., 2011). In addition, LOX-1 mediates oxLDL 3 
uptake by endothelial cells and impairs endothelium-dependent NO-mediated 4 
dilation of coronary arterioles by activation of a signaling cascade involving LOX- 5 
1 and NADPH oxidase (Shi et al., 2011). Anti-LOX-1 antibodies have been shown 6 
to restore nitric oxide-mediated coronary dilation in atherosclerotic APO-E null 7 
mice, but do not affect the endothelium-dependent vasodilation in wild-type mice 8 
(Xu et al., 2007). 9 
Recruitment of inflammatory cells to the endothelium is crucial in the 10 
development of atherosclerosis. Li and co-workers incubated human coronary 11 
artery endothelial cells (HCAEC) with oxLDL and demonstrated increased 12 
monocyte chemoattractant protein-1 (MCP-1) production as well as monocyte 13 
adhesion to HCAEC (Li and Mehta, 2000). This response was inhibited by human 14 
LOX-1 antisense RNA, suggesting that LOX-1 is a key factor in oxLDL-mediated 15 
monocyte adhesion in atherosclerosis. 16 
 17 
1.4.2 Smooth muscle cell migration and proliferation 18 
VSMC migration and proliferation is an important characteristic in 19 
atherosclerosis. OxLDL-induced LOX-1 expression stimulates VSMC growth and 20 
proliferation via NF-κB- and JNK-signaling; a process which has been inhibited 21 
by LOX-1 antisense mRNA in vitro (Xu et al., 2013). The link between VSMC 22 
proliferation and LOX-1 has been demonstrated in APO-E/LOX-1 double 23 
knockout mouse models of atherosclerosis (Mehta Jawahar et al., 2007) and in 24 
animal models of neointimal hyperplasia following balloon injury (Hinagata et al., 25 
2006). Hinagata and co-workers found that in rats administered anti-LOX-1 26 
antibody intravenously every 3 days after balloon injury, intimal hyperplasia, 27 
oxidative stress, and leukocyte infiltration were markedly suppressed. 28 
 29 
1.4.3 Macrophage foam cell formation 30 
As previously discussed macrophages express a wide range of SRs which bind 31 
and internalize oxLDL resulting in the formation of atherosclerotic foam cells (Li 32 
 30 
and Mehta, 2009). LOX-1 mediated uptake of oxLDL in macrophages stimulated 1 
by oxLDL and lysophosphatidylcholine, palmitic acids and hyperglycaemia 2 
(Schaeffer et al., 2009). 3 
 4 
1.4.4 Platelet activation and thrombosis 5 
The role of platelet activation in thrombosis is well described. Platelets have been 6 
found to internalize oxLDL, leading to down-regulation of platelet nitric oxide 7 
synthase activity and platelet aggregation (Chen, Mehta and Mehta, 1996). The 8 
LOX-1 receptor is expressed in platelets and has been shown to accumulate at 9 
the site of thrombus within the atherosclerotic plaque of patients with unstable 10 
angina pectoris (Chen et al., 2001b). Blocking LOX-1 with anti-LOX-1 antibody 11 
has been shown to diminish the formation of arterial thrombus in an animal model 12 
(Kakutani et al., 2000). Furthermore, it has been shown that variations in LOX-1 13 
polymorphisms within platelets affect platelet activation by oxLDL (Puccetti et al., 14 
2007). 15 
 16 
1.4.5 Hypertension 17 
The involvement of the renin-angiotensin system (RAS) in blood pressure 18 
homeostasis and the development of hypertension is well documented. It has 19 
been proposed that an interaction between LDL, especially oxLDL, and RAS 20 
activation is an important determinant of hypertension (Chen and Mehta, 2006). 21 
High levels of oxLDL upregulate angiotensin 2 receptor type 1 (AT1R) , and 22 
angiotensin 2 via AT1R induces the transcription of LOX-1. Cross-talk between 23 
oxLDL and RAS activation has been shown in laboratory animals (Chen et al., 24 
2006). APO-E null mice fed a high cholesterol diet showed limitation of 25 
atherosclerosis when simultaneously treated with the AT1R blocker candesartan 26 
or the HMG-CoA reductase inhibitor rosuvastatin, or both. In addition, the 27 
expression of LOX-1 as well as other pro-inflammatory and redox signals was 28 
completely blocked in the mice given the drug combination. 29 
Furthermore, Nagase and co-workers found that expression of LOX-1 mRNA in 30 
the aorta was up-regulated in hypertensive rats compared to normal healthy rats 31 
(Nagase et al., 1997). An in vitro study supported this hypothesis, which detected 32 
 31 
a marked increase in LOX-1 mRNA levels in cultured human coronary artery 1 
endothelial cells upon activation of AT1R (Li et al., 1999). 2 
 3 
1.5 LOX-1 as a biomarker in cardiovascular disease 4 
The association between SRs and cardiovascular disease is well established and 5 
multiple subtypes have been identified as having potential roles in genetic 6 
screening or as diagnostic and prognostic biomarkers. Screening for patients with 7 
a genetic predisposition to cardiovascular disease has potentially far reaching 8 
benefits in disease prevention and early management. Polymorphisms in genes 9 
encoding both CD36 and LOX-1 have been associated with increased overall 10 
cardiovascular risk (Che, Shao and Li, 2014; Jayewardene et al., 2014; Morini et 11 
al., 2016). A single-nucleotide polymorphism (SNP) of the OLR1 gene has been 12 
shown to improve the efficiency of LOX-1 expression in-vitro, suggesting that this 13 
may contribute to overall cardiovascular risk and may be useful in risk 14 
stratification (Morini et al., 2016). Moreover, a study of 150 patients with acute 15 
myocardial infarction versus 103 healthy controls identified SNPs in OLR1 16 
associated with increased risk of myocardial infarction (Mango et al., 2003). 17 
Measuring the concentration of circulating soluble biomarkers in serum is widely 18 
used in clinical practice to aid the diagnosis of acute coronary syndrome (Shah 19 
et al., 2018). SRs such as LOX-1 and CXCL16 have been identified as potential 20 
novel biomarkers in a range of cardiovascular disease states including acute 21 
coronary syndrome, cardiac failure, cardiomyopathy and carotid disease. A small 22 
clinical study of 67 patients found that serum soluble LOX-1 concentrations were 23 
significantly increased in acute coronary syndrome patients compared to those 24 
with stable angina pectoris (Misaka et al., 2014). The combination of serum 25 
soluble LOX-1 with troponin concentration improved diagnostic accuracy in acute 26 
coronary syndrome compared with each protein in isolation. The same study also 27 
found that soluble LOX-1 was comparable in accuracy in the diagnosis of acute 28 
coronary syndrome (Kobayashi et al., 2011). A study of 107 patients undergoing 29 
coronary stenting found that soluble LOX-1 was more accurate compared with 30 
troponin in the diagnosis of acute coronary syndrome and that combining both 31 
 32 
biomarkers improved accuracy above that of soluble LOX-1 in isolation (Kume et 1 
al., 2010).  2 
In vitro and in vivo animal models of heart failure have shown that LOX-1 is 3 
released by cardiac myocytes and promotes apoptosis (Iwai-Kanai et al., 2001; 4 
Kobayashi et al., 2006). To evaluate LOX-1 as a biomarker for systolic heart 5 
failure, serum soluble LOX-1 concentrations were measured in 55 patients with 6 
systolic heart failure and compared to concentration in 25 control subjects. Serum 7 
soluble LOX-1 concentrations were negatively correlated with left ventricular 8 
ejection fraction particularly in patients with ischaemia-related Aetiology (Besli et 9 
al., 2016). 10 
 11 
1.6 LOX-1 in cardiovascular disease therapeutics 12 
1.6.1 Clinically approved treatments 13 
Owing to their central role in the key pathways leading to atherosclerotic plaque 14 
formation, scavenger receptor inhibition or downregulation is an area of great 15 
interest in therapy for cardiovascular disease. Multiple avenues have been 16 
explored in drug discovery research including the efficacy of existing drugs, 17 
herbal medicines and novel therapeutics such as gene therapy and 18 
nanoparticles. 19 
Statin exposure reduces LOX-1 expression and its ability to bind oxLDL in vitro 20 
(Biocca et al., 2015). Additional studies demonstrating the reduction in LOX-1 21 
expression during statin therapy found additional benefits including increased NO 22 
production and reduced production of adhesion molecules (Mehta et al., 2001; Li 23 
et al., 2002a). The importance of the relationship between LOX-1 and statins is 24 
further highlighted by a cohort study of 751 patients with hypercholesterolaemia 25 
receiving statin therapy which found that LOX-1 genetic variations negatively 26 
influenced LDL reduction and cardiac risk (Puccetti et al., 2007). 27 
Other additional existing drugs have been shown to interact with LOX-1 including 28 
ursolic acid, histamine, spironolactone and ACE inhibitors. Ursolic acid was found 29 
to inhibit LOX-1 expression in vitro and significantly reduce both LOX-1 30 
expression and aortic atherosclerotic load in APO-E null mice (Li et al., 2018b). 31 
 33 
Similar results were obtained from a study of the same design when histamine 1 
was administered (Song et al., 2011). Anti-hypertensive medications such as the 2 
potassium sparing diuretic spironolactone and the ACE-inhibitor losartan have 3 
been shown to suppress LOX-1 expression and activity and thus hold potential 4 
in the prevention of atherosclerotic disease (Taye, Sawamura and Morawietz, 5 
2010; Morawietz et al., 1999). 6 
 7 
1.6.2 Herbal and traditional medicine therapies 8 
Herbal and traditional medicines have attracted some interest in scavenger 9 
receptor research relating to atherosclerosis. Ginkgo biloba extract also reduces 10 
LOX-1 expression both in combination and without aspirin, protecting against the 11 
oxidative effects of both oxLDL and activated platelets in cultured endothelial 12 
cells (Ma et al., 2013; Zhu et al., 2013). Cryptotanshinone, which occurs naturally 13 
in the herb Danshen has also been shown to attenuate atherosclerosis in APO- 14 
E null mice whilst significantly reducing LOX-1 expression and the production of 15 
adhesion molecules (Liu et al., 2015). 16 
 17 
1.6.3 Novel therapeutics 18 
LOX-1 targeting in atherosclerosis is an area of ongoing interest, owing to its well 19 
established role in multiple stages of the formation of atherosclerotic plaque (De 20 
Siqueira et al., 2015). Blocking LOX-1 in vitro has been shown to reduce the 21 
apoptotic effects of oxLDL co-incubation while transgenic animal studies have 22 
shown that LOX-1 knockout attenuates the development of atherosclerosis 23 
(Mehta Jawahar et al., 2007; Li et al., 2003). Studies investigating the use of anti- 24 
LOX-1 antibody in vivo report significant reductions in neointimal hyperplasia post 25 
balloon carotid artery injury and myocardial infarct size post coronary artery 26 
ligation (Hinagata et al., 2006; Li et al., 2002b). Additional reported effects of anti- 27 
LOX-1 antibody include reduced mesenteric artery lipid deposition in 28 
hypertensive rats and the attenuation of renal vascular fibrosis in obese diabetic 29 
hypertensive rats (Nakano et al., 2010; Dominguez et al., 2008). 30 
The role of microRNA (miRNA) in atherosclerosis is a relatively novel area of 31 
ongoing research aiming to identify potential new therapies. MiRNAs are tissue 32 
 34 
specific, small (∼22 nucleotides) non-coding RNAs which regulate expression of 1 
protein coding genes within cells involved in a wide range of pathological 2 
processes, including atherosclerosis (McDonald et al., 2012). Yao Dai et al. 3 
identified the LOX-1 targeting miRNA-98 using bio-informatics databases and 4 
demonstrated that administration of miRNA-98 affected a reduction in both lipid 5 
accumulation in vitro, and LOX-1 expression and aortic plaque accumulation in 6 
APO-E null mice (Dai et al., 2018). A similar study identifies miRNA let-7g in LOX- 7 
1 targeting and attenuation of atherosclerosis (Liu et al., 2017). The potential for 8 
miRNA to produce unwanted side effects due to off-target effects is concerning, 9 
however in the case of miRNA-98 this was addressed to some degree within the 10 
groups animal work and no obvious side effects or toxicity were detected (Dai et 11 
al., 2018). 12 
Using the high resolution crystal structure of LOX-1 to screen chemical libraries, 13 
novel molecules with potential LOX-1 affinity and inhibitory actions have been 14 
identified (Thakkar et al., 2015). Out of 5 screen-detected molecules, 2 produced 15 
the desired effect of reducing oxLDL uptake and monocyte adhesion to human 16 
endothelial cells. Chemical inhibitors have the potential advantage of producing 17 
less immunogenic side effects in comparison with antibody therapy, however 18 
their pharmacokinetics and effects in animal studies have yet to be determined. 19 
Single-chain variable fragment (scFv) antibodies targeting LOX-1 have only very 20 
recently been proposed as having therapeutic potential. According to recent 21 
reports, scFvs exhibit specific binding affinity, enhanced biodistribution and low 22 
immunogenicity compared with antibodies, while being potentially much cheaper 23 
to produce given that they can be expressed in bacterial cell culture (Fan et al., 24 
2014). Anti-LOX-1 scFvs are in the early stages of development and various 25 
methods have been employed aiming to improve binding affinity, thermostability 26 
and serum half-life including fusion with LOX-1 binding peptides and 27 
multimerization (Hu, Xie and Xiang, 2017; Hu et al., 2018). Small interfering RNAs 28 
(siRNA) developed to target LOX-1 mRNA inhibit downstream LOX-1/oxLDL 29 
mediated pathways in vitro (Arjuman and Chandra, 2017). The results are 30 
promising, however further evaluation in animal studies is needed to assess their 31 
ability to attenuate atherosclerosis. The challenges facing the development  of 32 
interference RNA technology are similar to that of other previously discussed 33 
 35 
alternatives to traditional antibodies, including off-target effects and the need for 1 
an effective delivery strategy (Gavrilov and Saltzman, 2012). 2 
 3 
1.7 LOX-1 linkage to other disease states 4 
1.7.1 Diabetes Mellitus 5 
Endothelial dysfunction leading to accelerated atherosclerosis occurs in diabetes 6 
mellitus, hence the potential link between LOX-1 activity and diabetes mellitus 7 
has been investigated. In 2001, Chen and co-workers examined vascular LOX-1 8 
expression in streptozotocin-induced diabetic rats, finding that LOX-1 expression 9 
was significantly increased in diabetic rate aorta compared with controls (Chen 10 
et al., 2001c). In a human study, serum sLOX-1 concentration was found to be 11 
significantly higher in patients with diabetes compared with those without and 12 
reduced in response to improved glycaemic control (Tan et al., 2008). Serum 13 
sLOX-1 has been proposed as a marker for peripheral arterial disease in patients 14 
with type 2 diabetes mellitus. The authors demonstrated a significant inverse 15 
correlation between serum sLOX-1 and ankle-brachial pressure index in a group 16 
of 27 patients with known T2DM and peripheral arterial disease (Fukui et al., 17 
2013). 18 
 19 
1.7.2 Neoplasia 20 
OxLDL and LOX-1 are involved in mechanisms linked to tumour genesis such as 21 
cell transformation state in diverse cancer cell lines and in tumour growth (Lu et 22 
al., 2011). Moreover, individuals with atherosclerotic plaques and high levels of 23 
circulating ox-LDL and LOX-1 expression seem to be more prone to develop 24 
cancer, implying a mechanistic overlap in the pathobiology of atherogenesis and 25 
tumorigenesis which most likely involves the generation of reactive oxygen 26 
species secondary to LOX-1 - oxLDL binding and subsequent oxidative DNA 27 
damage (Balzan and Lubrano, 2018). 28 
The depletion of LOX-1 protects against tumour-genicity, motility and growth of 29 
cancer cells. The beneficial effects exerted by LOX-1 depletion are common 30 
among several lineages, such as hepatocellular carcinoma, breast and cervical 31 
 36 
cancers (Hirsch et al., 2010). Furthermore, LOX-1 was shown to be upregulated 1 
in 57% of bladder and cervix cancer cells, 11% of mammary gland cancer cells, 2 
10% of lung cancer cells and in 20% of colorectal cancer cells in a meta-analysis 3 
of gene expression profiles of about 950 cancer cell lines (Murdocca et al., 2016). 4 
Further studies have found the expression of LOX-1 is significant in gastric, 5 
colorectal, pancreatic and hepatocellular carcinoma (Balzan and Lubrano, 2018). 6 
 7 
1.7.3 Sepsis and inflammation 8 
The role of oxLDL and LOX-1 in leukocyte activation and microvascular perfusion 9 
disturbances has been demonstrated in an experimental endotoxaemia model in 10 
rats (Landsberger et al., 2010). OxLDL and LOX-1 may play a role in the 11 
increased inflammation and capillary leakage, two factors associated with 12 
disturbances in the microcirculation in sepsis. LOX-1 null mice had improved 13 
survival in a caecal ligation and puncture (CLP) sepsis model. LOX-1 null mice 14 
also had lower inflammatory response to CLP, in terms of pro-inflammatory 15 
cytokine levels (e.g., TNF-alpha) in the serum and the extent of lung oedema. 16 
These mice were also able to clear the bacteria from peritoneum, blood, and 17 
lungs more than wild mice (Wu et al., 2011). 18 
The destruction of articular cartilage in rheumatoid arthritis is mediated by a 19 
series of proteinases (Burrage, Mix and Brinckerhoff, 2006). Matrix- 20 
metalloproteinases (MMP), namely MMP-1 and MMP-3 play pivotal roles and are 21 
potent biomarkers for joint destruction (Ribbens et al., 2002). Kakinuma and co- 22 
workers found an increase in MMP-3 synthesis in articular cartilage cells upon 23 
activation of LOX-1 by oxLDL (Kakinuma et al., 2004). Ishikawa and co-workers 24 
demonstrated that oxidative modification of LDL in the synovium human 25 
rheumatoid joints is increased. The authors blocked the production of MMP-3 by 26 
inhibiting the interaction between LOX-1 and oxLDL with LOX-1 specific antibody 27 
(Ishikawa et al., 2012). This suggests that LOX-1 is a potential target in the 28 




1.8 Non-antibody artificial binding proteins 1 
1.8.1 Introduction 2 
The utility of antibodies in therapeutics is well documented. Research and 3 
development in antibody therapy in cardiovascular and most other disease states 4 
continues (Nakagami, 2017; Ohta et al., 2017; Akaishi and Nakashima, 2017; 5 
Levy, 2000; Wang and Weiner, 2008). As therapeutic agents, there are several 6 
advantages in the use of antibodies. Antibodies can be quickly generated against 7 
a wide range of target proteins and exhibit levels of affinity (in the low nanomolar 8 
or picomolar range) and specificity to their targets which surpass most chemical 9 
drugs (Gebauer and Skerra, 2009). With the wide acceptance and increasing 10 
application of antibody therapy, significant limitations have emerged. They are 11 
large multimeric proteins that require disulphide bonds and glycosylation for 12 
stability, thus their manufacture involves eukaryotic expression systems and 13 
transfection of mammalian cell lines – the optimization and fermentation of which 14 
is a lengthy and costly process (Gebauer and Skerra, 2009). Antibodies are often 15 
highly sensitive to higher temperatures, potentially impacting on clinical efficacy 16 
while increasing transportation and storage costs (Tiede et al., 2014).  17 
A variety of non-antibody artificial binding proteins have been developed to 18 
overcome the limitations of antibodies while mimicking their molecular recognition 19 
properties. In contrast to antibodies, artificial binding proteins are generally small, 20 
monomeric, thermostable and easily expressed in bacterial cell culture (Tiede et 21 
al., 2014). In general, artificial binding proteins structurally comprise of a highly 22 
stable protein scaffold and a variable binding region. To name a few, these 23 
include ankyrin repeat proteins (DARPins), Repebodies, Anticalins, Fibronectins, 24 
Affibodies and engineered Kunitz domains (Table 2.1) (Binz et al., 2003; Lee et 25 
al., 2012; Schlehuber and Skerra, 2005; Koide et al., 1998; Nord et al., 1995; 26 
Nixon and Wood, 2006).  27 
 28 
  29 
 38 
Table 1.2. Synthetic or artificial protein technologies 1 
Adapted from cited references (Skerra, 2007; Škrlec, Štrukelj and Berlec, 2015; 2 
Martin et al., 2018). 3 
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1.8.2 Non-antibody artificial binding proteins: general principles 2 
 3 
1.8.2.1 Scaffold design and consensus sequence 4 
Enhanced thermostability of therapeutic compounds broadens the range of 5 
processes suitable for purification (e.g. heat purification), and the options 6 
available for storage and administration. One design-approach to improve 7 
thermostability in artificial protein scaffolds is the use of consensus sequence 8 
design. The consensus sequence approach to protein stabilization is based on 9 
the hypothesis that random mutations which lead to protein destabilization have 10 
a high probability of occurring during natural and in vitro evolution processes, but 11 
do not cause the stability of the protein to fall below a level that renders it inactive, 12 
therefore remaining functionally neutral. Random mutations that increase the 13 
protein stability are assumed to be much less probable due to a lack of positive 14 
selection for such increases in stability. Thus, amino acid positions in homologs 15 
that have a strongly conserved consensus residue are thought to contribute more 16 
to the stability than those positions without a clear consensus (Jacobs et al., 17 
2012). In basic terms, consensus design aims to identify frequently occurring 18 
residues at a given position (consensus residues), as they are likely to optimize 19 
stability in this position. By averaging over many residue sequences that share 20 
the same structure and function, a consensus sequence of residues is formulated 21 
(Sternke, Tripp and Barrick, 2019). Scaffold stability is particularly important in 22 
artificial binding proteins given that the insertion of variable binding regions can 23 
reduce stability (Skerra, 2007). In the affimer scaffold sequence, the inhibitory 24 
sequences within 2 loops are each replaced with a randomized sequence of 9 25 
amino acids (Tiede et al., 2014).  26 
 40 
 1 
1.8.2.2 Phage display 2 
The randomized amino acid sequences within the variable binding region of the 3 
protein offer the possibility of generating binding proteins to a wide range of 4 
molecular targets. Affimers use phage display technology to generate binding 5 
proteins specific to molecular targets. Alternative techniques exist in this field, 6 
including ribosome display, mRNA display, CIS display, DNA display and yeast 7 
two-hybrid system, which are not discussed. In basic terms, the phage display 8 
technique is performed in the following stages (Figure 1.7):  9 
• Recombinant DNA coding for the artificial binding protein is amplified by 10 
PCR. PCR primers are designed to introduce a sequence of degenerate 11 
trimers (NNN), corresponding to the variable binding regions. 12 
• The recombinant DNA is cloned in to a phagemid vector which is then 13 
transformed in to competent E. Coli cells. 14 
• Phage expression by E. Coli cells is induced. During transcription, the 15 
degenerate sequence gives rise to mutagenesis and thus coding for random 16 
amino acid sequences within the variable binding regions of the protein. 17 
• The phages are extracted from the E. Coli cells and suspended in solution. 18 
Each phage expresses a binding protein with a specific binding region on 19 
its surface. The solution will contain populations of phages, each population 20 
expressing on its surface a binding protein with a different binding region – 21 
the phage display library. 22 
• The target protein is purified and immobilised in wells. The phage library is 23 
added to the wells and binders with affinity to the target protein isolated by 24 
washing and elution steps. Eluted phage is transfected in to E. Coli cells 25 
and the process is repeated in a series of panning steps. 26 
• Highly specific high-affinity binding proteins are thus isolated from the 27 
library. Following phagemid DNA sequencing, a plasmid DNA vector 28 
encoding the isolated binding protein is created using recombinant DNA 29 
techniques.  30 
• Plasmid DNA can then be transformed in to competent bacterial cells, 31 
allowing inducible protein expression and the extraction and purification of 32 





Figure 1.7. The basic concepts of phage display. A phage display library is 4 
incubated with immobilised target protein to isolate phages expressing specific 5 
binding proteins. DNA coding for specific binding proteins can be expressed in 6 
bacterial cells and purified for use as an affinity agent. 7 
1.8.3 Affimers 8 
At the University of Leeds M. McPherson and D. Tomlinson have developed and 9 
patented a non-antibody artificial protein scaffold named “Affimer” (Tiede et al., 10 
2014; Tiede et al., 2017). Affimers are synthetic proteins based on a consensus 11 
sequence of plant-derived phytocystatins which are easily expressed in bacterial 12 
cell culture and highly thermostable (Tm = 101°C) (Tiede et al., 2014). The 13 
Affimer protein comprises the characteristic cystatin family fold of a four-strand 14 
anti-parallel β-sheet core with a central helix and contains two variable binding 15 
regions (Figure 1.8) (Tiede et al., 2014). A phage-display library of variable 16 
proteins has the potential to generate distinct binding proteins to a wide range of 17 
ligands (Tiede et al., 2014). To-date, affimers specific to multiple target proteins 18 
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have been generated and tested in a range of applications with translational 1 
potential (Tiede et al., 2017): 2 
• The development of MRI reagent (trivalent Gd-DOTA reagents). 3 
• Affinity histochemistry (anti-tenascin C affimer, anti-VEGFR2 affimer). 4 
• In-vivo imaging (anti-tenascin C affimer). 5 
• Biosensor technology (anti-myc affimer, anti-IL8 affimer). 6 
• Modulators of protein function (anti-p85 affimer, anti-VEGFR2 affimer, anti- 7 
TRPV1 affimer). 8 
 9 
1.9 Hypothesis, aims and objectives 10 
My scientific hypothesis is that LOX-1 is a key mediator of of the pro-atherogenic 11 
response in vitro and in vivo. The long-term aim or goal is to develop therapeutics 12 
that could be clinically useful for vascular disease treatments. Specific 13 
experimental objectives to answer the hypothesis are: 14 
• Test Affimers specific for LOX-1 using a tightly regulated cell expression 15 
system.	 16 
• Investigate whether LOX-1 is required for atherosclerosis in vivo.	 17 









Figure 1.8. Basic structure of the affimer protein. The affimer protein 4 
comprises the characteristic cystatin family fold of a four-strand anti-parallel β- 5 
sheet core with a central helix and contains two variable binding regions 6 
(interaction loop 1 & 2). 7 
 8 
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CHAPTER 2 1 
MATERIALS AND METHODS 2 
 3 
2.1 Materials 4 
2.1.1 Chemical reagents and antibodies 5 
All chemicals were purchased from VWR, Sigma or Melford Laboratories unless 6 
stated otherwise. Bicinchoninic acid assay (BCA assay) was from ThermoFisher 7 
(Cramlington, UK) or Pierce (Rockford, USA). Enhanced chemiluminescence 8 
(ECL) reagents for Western blotting were from ThermoFisher (Cramlington, UK). 9 
Oligonucleotide primers were from Sigma-Aldrich (Poole, UK) or Integrated DNA 10 
Technologies (Coralville, USA). Cell culture media and reagents were from 11 
Invitrogen (Amsterdam, Netherlands). Isofluorane was purchased from Central 12 
Business Services at the University of Leeds. 13 
 14 
2.1.2 Antibodies 15 
The following antibodies were purchased: mouse anti-FLAG (Sigma-Aldrich, 16 
Poole, UK), goat polyclonal anti-LOX-1 (R+D Systems, Minneapolis, USA), 17 
horseradish peroxidase (HRP)-conjugated secondary antibody (Thermo Fisher, 18 
Cramlington, UK), AlexaFluor-488, -594 conjugated secondary antibodies 19 
(Invitrogen, Amsterdam, Netherlands). The following antibodies were produced 20 
by the Ponnambalam laboratory: sheep anti-LOX-1 (Diagnostics Scotland, 21 
Edinburgh, UK), rabbit anti-LOX-1 (Eurogentec, Seraing, Belgium). 22 
 23 
2.1.3 Cell lines 24 
The XL-10 gold Escherichia coli (E.coli) strain (TetrΔ(mcrA)183 Δ(mcrCB- 25 
hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA1 gyrA96 relA1 lac Hte [F’ 26 
proAB laclqZDM15 Tn10 (Tetr) Amy Camr) was from Stratagene (CA, USA). The 27 
XL-10 gold strain was used for plasmid propagation and cloning. Tetracycline- 28 
inducible LOX-1 expressing and empty vector human embryonic kidney - 29 
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HEK293T cells were kindly provided by Dr. Izma Abdul Zani (University of Leeds, 1 
UK). 2 
 3 
2.1.4 Transgenic mice 4 
LOX-1 knockout mice on the C56BL/6 background were kindly gifted by 5 
Professor Tatsuya Sawamura (National Cerebral and Cardiovascular Centre, 6 
Osaka, Japan). APO-E knockout and wild-type (C57Bl/6J) mice were purchased 7 
from Charles River (Charles River Laboratories, Margate, UK). Mice were housed 8 
in a custom-built transgenic animal facility run by Central Biomedical Services at 9 
the University of Leeds. 10 
 11 
2.1.5 Surgical equipment 12 
All dissections were performed using instruments purchased from World 13 






Figure 2.1. Surgical instruments for animal and histological work. (A) Micro- 20 
dissecting scissors, (B) Kuehne Coverglass/Specimen Forceps, (C) Fine tip 21 
handling forceps, (D) Curved handling forceps, (D) Various straight handling 22 
forceps, (E) Metzenbaum dissecting straight scissors, (F) Iris dissecting scissors, 23 
(G) No. 3 Scalpel handle. 24 
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2.2 Experimental methods 1 
2.2.1 Protein chemistry and analysis 2 
 3 
2.2.1.1 Preparation of competent E.coli cells 4 
E.coli XL-10 Gold cells were grown on Luria-Bertani (LB) agar (1% (w/v) bacto- 5 
tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCl and 1.5% (w/v) agar (pH 6 
7.0) overnight at 37°C. A single colony was then inoculated into 50 ml of LB media 7 
(1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract and 1% (w/v) NaCl, pH 8 
7.0) and grown for ~24 h at 37°C with shaking. The stationary phase bacteria was 9 
then diluted 1:20 in fresh LB and grown until an OD550-600 of ~0.3-0.6 was 10 
reached. The culture was then chilled on ice for up to 15 min followed by 11 
centrifugation for 5 min at 3000 g at 4°C. Cells were then resuspended in a small 12 
amount of residual LB by vortexing. 20 ml of ice-cold Tfb I (30 mM potassium 13 
acetate, 100 mM RbCl2, 50 mM MnCl2, 10 mM CaCl2 and 15% (v/v) glycerol, 14 
pH 5.8) was added per 50 ml of culture and cells resuspended in the buffer then 15 
incubated on ice for up to 45 min. Cells were centrifuged for 10 min at 3000 g at 16 
4°C. The pelleted cells were then resuspended in 4 ml ice-cold Tfb II (10 mM 17 
MOPS, 75 mM CaCl2, 10 mM RbCl2 and 15% (v/v) glycerol, pH6.5) and 18 
incubated on ice for 30 min. Cells were aliquoted and snap frozen on dry ice 19 
before storage at -70°C. 20 
 21 
2.2.1.2 Transformation into competent E.coli cells 22 
10 μl of competent E.coli XL-10 Gold cells were added to the DNA and incubated 23 
on ice for 5 min. Cells were heat shocked at 42°C for 1 min, and returned to ice 24 
for 3 min. Cells were plated onto LB plates containing the appropriate antibiotic 25 
and incubated at 37°C overnight. 26 
 27 
2.2.1.3 Small scale DNA purification 28 
5 ml of LB plus appropriate antibiotic was inoculated with a single colony of XL10 29 
E. coli cells and grown at 37°C for 16 h in a shaking incubator. 1.5 ml was pelleted 30 
by centrifugation at 16000 g. Plasmid DNA was then purified using the Qiagen 31 
miniprep kit (Hilden, Germany) according to the manufacturer’s instructions. 32 
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 1 
2.2.1.4 Affimer expression in competent E.coli cells 2 
BL21*DE3 cells were thawed on ice. 1.5 µl of plasmid DNA is incubated with 10 3 
µl of BL21*DE3 cells for 30 min, followed by heat shock at 42°C for 45 sec. 450 4 
µl of SOC medium was added and incubated at 37°C for 1 h at 180-200 rpm. 5 
Cells were centrifuged at 4000 rpm and most of media removed, with ~100 µl 6 
liquid remaining. The pellet was resuspended in the remaining supernatant and 7 
plated on to LB agar + ampicillin (50 µg/ml) and incubated overnight at 37°C. 8 
 9 
2.2.1.4.1 Inducing Affimer expression with isopropyl β-D-1- 10 
thiogalactopyranoside (IPTG) 11 
A chosen colony from the LB agar plate was added to 3ml of LB + 1:1000 12 
ampicillin and incubated overnight at 37°C. 1ml of culture was added to 50ml of 13 
LB + 1:1000 ampicillin and grown until optical density at 600nm reaches 0.6-0.8. 14 
At this point affimer expression was induced by adding IPTG to a final 15 
concentration of 0.1nM (5µl) and incubated for 6 hours at 25°C at 150rpm. 16 
 17 
2.2.1.4.2 Affimer purification 18 
Buffers were prepared as follows: 19 
• Lysis buffer: 50 mM NaH2PO4; 300 mM NaCl; 20 mM Imidazole; 10% (v/v) 20 
Glycerol; pH 7.4 	 21 
• Wash buffer: 50 mM NaH2PO4; 500 mM NaCl; 20 mM Imidazole; pH 7.4	 22 
• Elution buffer: 50 mM NaH2PO4; 500 mM NaCl; 300 mM Imidazole; 10% 23 
(v/v) Glycerol; pH 7.4	 24 
5 µl of 20 mg/ml lysozyme (0.1 mg/ml), 10 µl Triton X-100, 0.4 µl Benzonase, and 25 
10µl 100 mM PMSF (1 mM) were added to 1 ml of lysis buffer, mixed and 26 
subsequently added to the cell pellet and vortexed. This was then sonicated and 27 
placed on a rotator wheel at 4°C for 20 min. This was then placed in a water bath 28 
at 50°C for 20 min. The lysate was then centrifuged to remove cell debris. The 29 
supernatant was incubated for 2 h with pre-washed (with lysis buffer) Ni-NTA 30 
agarose slurry at 4°C, then centrifuged to remove unbound protein. The cell pellet 31 
/ Ni-NTA agarose slurry was placed in a 5 ml Pierce centrifuge column and 32 
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washed with lysis buffer 5x, followed by wash buffer 10x, or until A280 reading 1 
was <0.01. 500 µl of elution buffer was added to the column, incubated for 5 mins 2 
and collected off the column. Affimers were either biotinylated, conjugated with 3 
Alexafluor-488 or dialysed into PBS Affimers were analysed by BCA and SDS- 4 
PAGE and concentrations ranged from 0.1-5 mg/ml. Affimers were snap frozen 5 
and stored in 50 µl aliquots at -70°C. .  6 
 7 
2.2.1.5 Biotinylation of Affimers 8 
Affimers with C-terminal cysteine were biotinylated directly after elution from the 9 
nickel-agarose column. For each Affimer, 150 ml Tris (2-carboxyethyl)phosphine 10 
(TCEP) immobilised resin (ThermoFisher Scientific) was washed and incubated 11 
with 150 ml of 40 mM Affimer solution on a rocker for 1 h. The solution was 12 
centrifuged for 1 min at 1500 g and 120 ml of the supernatant was transferred 13 
into a fresh tube containing 6 ml of 2 mM biotin-maleimide (Sigma) and incubated 14 
for 2 h at room temperature. Excess biotin linker was removed by using a Zeba 15 
spin desalting column (ThermoScientific) according to the manufacturer’s 16 
protocol. 17 
 18 
2.2.1.6 Labelling Affimers with Alexafluor-488 maleimide 19 
The C-terminal cysteine residues were labelled with Alexafluor-488 maleimide. 20 
Affimers in elution buffer was pre-treated with TCEP resin. A 10 mM stock 21 
solution of Alexafluor-488 was made up in DMSO. This stock solution was added 22 
to the protein solution dropwise while stirring to produce approximately 10-20 23 
moles of reagent per mole of protein, and the reaction proceeds at room 24 
temperature for 2 h protected from light. Excess reagent was removed from 25 
solution using a Zeba spin desalting column (ThermoFisher Scientific) according 26 






2.2.1.7 Preparation of oxLDL 4 
Buffers and solutions are prepared as follows: 5 
 6 
Hepes buffered saline (HBS): 7 
• 16 g NaCl per litre 8 
• 0.4 g Na2HPO4.7H2O (can use dibasic salt as well; important thing is that 9 
final phosphate conc. is 1.5 mM) 10 
• 13 g Hepes 11 
• ddH2O to final volume 1 L 12 
 13 
Sudan black: 14 
• Make 200 ml of 60% ethanol in glass beaker 15 
• Place on stirring platform and heat to 37ºC 16 
• Place a magnetic stirrer in the beaker when temperature has reached 37ºC 17 
• Stir in Sudan black powder until saturated (about or less than 0. 5g of Sudan 18 
black) 19 
• Cool solution to room temperature 20 
• Filter Sudan black using filter paper into 50 ml sterile plastic tube 21 
• Into each 50 ml of Sudan black, add 0.1 ml of 25% (w/v) NaOH solution 22 
 23 
2.2.1.7.1 Preparation of LDL 24 
18 ml of blood (donated by human volunteers under University of Leeds local 25 
ethics approval #BIOSCI 15-007) was drawn and transferred to a 50 ml sterile 26 
plastic tube containing 2 ml of 3.8% (w/v) trisodium citrate (9:1 ratio). Whole blood 27 
was centrifuged at 3000 rpm for 10 min at 4ºC and plasma (supernatant) was 28 
pipetted off and transferred to a new tube. OptiPrep (Sigma) was added at a 4:1 29 
ratio. Using pipette-boy with sharp glass tip, plasma was transferred into 30 
Beckman centrifuge tubes containing 1 ml HBS, filling it to the top and placing 31 
black bungs and tube collars on all tubes. After balancing tubes, they were placed 32 
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in Beckman TL-110 rotor using a Beckman Optima-MAX centrifuge running at 1 
100 000 g for 3 h at 16ºC. Tubes were wrapped in cellotape and placed in clamps. 2 
A 25-gauge needle and 1 ml syringe was used to aspirate the LDL band, which 3 
appeared bright yellow/orange (Figure 2.2). The LDL was then dialysed against 4 





Figure 2.2. Preparation and oxidation of LDL. Plasma was extracted from 10 
whole blood and spun at 100,000 g for 3 h, separating the LDL from HDL, LDL 11 
and VLDL. LDL is then removed and oxidized by addition of CuSO4. HDL; high- 12 
density lipoprotein. LDL; low-density lipoprotein. VLDL; very low-density 13 
lipoprotein.  14 
 15 
 16 
2.2.1.7.2 Oxidation and analysis of LDL and oxLDL 17 
LDL fraction was transferred to tube and add 5 µM CuSO4 was added and the 18 
mixture incubated at 37ºC for 24 h, wrapped in tinfoil. After 24 h, 100 µM EDTA 19 
and 20 µM BHT was added and solution placed on ice. The oxLDL should have 20 
changed colour from yellow LDL to a clear solution. After dialysis against PBS, 21 
oxLDL concentration was determined by BCA assay, then LDL and oxLDL were 22 
subjected to agarose gel electrophoresis at quantity of 4 µg in each lane. The 23 
agarose gel was then added to container containing solution of 75% (v/v) ethanol 24 
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and 5% (v/v) acetic acid and incubated at room temperature for 15 min. The 1 
solution wa then drained off and Sudan black stain was added to the gel and 2 
incubated at room temperature for 3 h, wrapped in foil. After draining off Sudan 3 
black, the gel is washed twice with 50% (v/v) ethanol and left overnight in 50% 4 
(v/v) ethanol, wrapped in tinfoil. The gel was then ready for imaging. Successful 5 
oxidation is demonstrated by increased electrophoretic migration of the oxLDL 6 
towards the positive anode (red) compared to LDL on the same gel. 7 
 8 
2.2.1.8 DiI-labeling of oxLDL 9 
OxLDL particles were labelled with the fluorescent compound 1,1 dioctadecyl- 10 
3,3,3’,3’-tetramethyllindocarbocyanine perchlorate (DiI; Sigma) in DMSO. 300 μg 11 
of DiI was added to each milligram of lipoprotein and incubated in the dark at 12 
37°C for 18 h. The labelled oxLDL was then centrifuged at 13,000 rpm for 10 min 13 
before dialysing against PBS in the dark for 24 h at 4°C. The concentration of DiI- 14 
oxLDL was measured by BCA assay. 15 
 16 
2.2.2 Protein analysis 17 
 18 
2.2.2.1 Preparation of cell lysates 19 
Media was aspirated from flasks and cells were washed twice in cold PBS. Cells 20 
were then lysed in 2% (w/v) SDS in PBS containing 1 mM PMSF and protease 21 
inhibitor cocktail (Roche) and scraped into microcentrifuge tubes. This was 22 
followed by incubating lysates at 95°C for 5 min and sonicated for 5 sec. 23 
 24 
2.2.2.2 BCA assay 25 
After preparing lysates, total protein concentration can be quantified by 26 
bicinchoninic acid (BCA) assay. On a 96-well plate, 10 μl of standard bovine 27 
serum albumin (BSA) controls at different concentration of 0, 0.2, 0.4, 0.6, 0.8, 28 
1.0 mg/ml and 5 μl of protein samples were added in duplicates. Reagents A and 29 
B of Pierce BCA protein assay (ThermoFisher Scientific, Massachusetts, US) 30 
were mixed together in a 50:1 ratio, and 200 μl of the mixture was added into 31 
each well. The plate was then incubated at 37°C for 20 min, followed by reading 32 
at 562 nm using a Tecan plate reader connected to a PC running on Magellan 33 
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version 6.0 software (Tecan, Reading, UK). Values were obtained from it to 1 
calculate the maximal amount of sample to be loaded for SDS-PAGE gel and 2 




2.2.2.3 SDS-PAGE electrophoresis 7 
Buffers and gels were prepared as follows: 8 
 9 
2X SDS-PAGE sample buffer: 10 
• 100 mM Tris, pH 6.8 11 
• 4% (w/v) SDS 12 
• 20% (v/v) glycerol 13 
• 0.1% (w/v) 50nM bromophenol blue 14 
• 4% (w/V) β-mercaptoethanol 15 
 16 
Running gel mix: 17 
Solution
s 
Vol. (ml) required for different percentage gels 





























































5.1 10.2 4.45 8.9 3.45 6.9 
10% 
SDS 
0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 
APS 0.2 0.4 0.2 0.4 0.2 0.4 0.2 0.4 0.2 0.4 0.2 0.4 
TEMED 8µl 16µl 8µl 16µl 8µl 16µl 8µl 16µl 8µl 16µl 8µl 16µl 
 18 
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5% Stacking Gel Mix: 1 
Can be made fresh each month and stored in the fridge at 4ºC 2 
For 200 ml: 3 
Solution Volume (ml) 
30% Acryl 33.3 
1 M Tris 25 
10% SDS 2 
ddH2O 139.7 
	 4 
Protein samples were added to an equal volume of 2X SDS-PAGE sample buffer. 5 
Samples were briefly centrifuged (maximum speed, 10 sec) to collect all droplets. 6 
To separate proteins, 15% SDS-PAGE gels were made up and the gels were 7 
allowed to set for >15 min. Samples were loaded in a 5% stacking gel and 8 
subjected to electrophoresis in a discontinuous running buffer (25 mM Tris, 192 9 
mM glycine, 0.1% (w/v) SDS) at 130V for ~2 h. 10 
 11 
2.2.2.4 Western blotting 12 
Buffers were prepared as follows: 13 
Transfer buffer: 14 
• 400 ml Methanol 15 
• 1200 ml ddH2O 16 
• 200 ml 10x transfer buffer  17 
 18 
TBS-T: 19 
• 10 mM Tris, pH 7.5  20 
• 150 mM NaCl  21 
• 0.1% Tween-20 22 
Four 6x16.5 cm strips of 3MM Whatman blotting paper and one 6x16.5 cm strip 23 
of nitrocellulose membrane per gel were pre-soaked in transfer buffer. A trimmed 24 
protein gel was inverted on to the 0.2 µm pore size nitrocellulose membrane 25 
(BioRad) and sandwiched between 2 strips of blotting paper either side. Air 26 
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bubbles are removed and the gel sandwich is placed in to a transfer cassette. 1 
The cassette was then placed in to a transfer tank filled with transfer buffer. 2 
Transfer was performed at 300 mA for 3 h or overnight (~16 h) at 30 mA at 4°c. 3 
To confirm transfer is complete, the nitrocellulose membrane was removed and 4 
placed in a glass dish containing enough Ponceau S solution to cover the 5 
membrane. Visible bands confirm successful transfer of proteins to the 6 
membrane. Ponceau S solution was poured back to its bottle for re-use. 7 
Remaining Ponceau S was rinsed off with ddH2O followed by washes with TBS- 8 
T. The membrane was then incubated in 50 ml (or enough to cover the 9 
membrane) 1-5% (w/v) non-fat skimmed milk in TBS-T for ≥ 30-60 min, followed 10 
by rinsing with TBS-T. 1° antibody was diluted into 1% (w/v) non-fat skimmed 11 
milk in TBST to 1:1000-10 000 of serum final concentration. The nitrocellulose 12 
membrane was incubated on a rocker in 10 ml of 1° antibody overnight or over 13 
the weekend at 4°C in a sealed plastic bag. 1° antibody solution was then 14 
removed and membrane was washed 3 times with TBS-T. 2° antibody was 15 
diluted to 1:2500 in 10 ml TBS-T with1% milk and then added to washed 16 
membrane blot and incubated on a rocker for 1 h at room temperature. The 2° 17 
antibody was removed and the membrane is washed 3 times for 10 min each 18 
time with TBS-T. A working concentration of enhanced chemiluminescence 19 
(ECL) solution was made up by mixing reagents A and B in a 1:1 ratio (500 μl 20 
total volume per membrane strip). The ECL solution was pipetted onto a sheet of 21 
plastic acetate covering an area that corresponds to the size of the membrane 22 
and the membrane blot was inverted a few times onto the ECL solution, ensuring 23 
no air bubbles are trapped between the membrane and acetate sheet. After 24 
leaving to stand for 1 min, the membrane blot was sandwiched with another 25 
plastic acetate sheet, and with protein-antibody sandwich facing upwards, placed 26 
inside the chemiluminescence workstation for digital imaging.  27 
 28 
2.2.2.5 Cross-reactivity ELISA using Affimers 29 
Buffers were prepared as follows: 30 
Buffer A:  31 
• 0.0025 M NaH2PO4.2H2O  32 
• 0.0075 M Na2HPO4.2H2O 33 
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• 0.145 M NaCl  1 
• pH 7.2 2 
 3 
Buffer B:  4 
• To 1 L of Buffer A, add: 5 
§ 2 ml Tween-20  6 
§ 20.75 g NaCl 7 
 8 
 9 
Buffer E:  10 
• 1.5 M H2SO4 11 
 12 
An Immunosorp 96-well ELISA plate (Nunc) was coated with 100 µl triplicates of 13 
0.1 and 1.0 µg/ml of human and mouse soluble LOX-1 protein in buffer A 14 
overnight. Plate was then washed and blocked with 1% (w/v) BSA. 100 µl of 1 15 
µg/ml biotinylated Affimer in buffer B was added to each well and incubated for 2 16 
h at room temperature on plate shaker. Streptavidin-HRP was then added to each 17 
well at 1 µg/ml in buffer B and incubated for 1 h at room temperature on plate 18 
shaker. 100 µl of TMB liquid substrate (Sigma-Aldrich) was then added to each 19 
well after washing and reaction stopped after 30 min with buffer E. 20 
 21 
2.2.3 Cellular studies 22 
 23 
2.2.3.1 Cell culture 24 
Epithelial human embryonic kidney 293 (HEK293) cell line and Flp-InTM T- 25 
RexTM -293 cell line were cultured in Dulbecco’s modified eagle medium 26 
(DMEM; Gibco, Cramlington, UK) containing 10 U/ml penicillin, 100 μg/ml 27 
streptomycin, 2 mM L-Glutamine, 1X non-essential amino acids and 10% (v/v) 28 
foetal calf serum (FCS; Life Technologies, Paisley, UK). 29 
Cells were incubated at 37°C in a hydrated 5% CO2 atmosphere and passaged 30 
every 2-3 days by incubation with PBS-EDTA. Cells were incubated with PBS- 31 
EDTA at 37°C for 3-5 min. PBS-EDTA solution was then carefully aspirated from 32 
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the plate. The plate was then tapped gently 5 times before cells were washed off 1 
using DMEM and split at the appropriate ratio. If plating on to coverslips, 2 
coverslips were coated with filter-sterilized poly-l-lysine (1 mg/ml) / pig skin 3 
gelatin (0.05% w/v) mixture in PBS for 1-2 h in a 24-well plate. The mixture was 4 
then aspirated from the coverslip and cells resuspended in DMEM were plated 5 
on to the coverslip in aliquots of 300 µl at an appropriate confluence.  6 
 7 
2.2.3.2 Immunofluorescence analysis 8 
Media was aspirated from cells seeded on poly-l-lysine (Sigma-Aldrich, Poole, 9 
UK) coated coverslips in 24-well plates and cells were rinsed twice in PBS. Cells 10 
were fixed in 500 μl 10% (v/v) formalin (Sigma-Aldrich, Poole, UK) for 5 min at 11 
37°C. Fixative was aspirated and coverslips rinsed twice in PBS. Coverslips were 12 
then incubated in 0.5% (w/v) BSA in PBS to block non-specific antibody binding 13 
to cells, followed by washing twice in PBS. Coverslips were inverted onto a 25 μl 14 
drop of primary antibody solution diluted in 0.1% (w/v) BSA in PBS (Table 2.1) in 15 
a moist staining chamber and incubated overnight at room temperature. 16 
Coverslips were washed 3 times with PBS and inverted onto a 25 μl secondary 17 
antibody solution containing 4 μg/ml donkey Alexa Fluor-conjugated secondary 18 
antibody (Invitrogen, Amsterdam, Netherlands), 2 μg/ml 4,6-diamidino-2- 19 
phenylidole (DAPI) in 1% (w/v) BSA in PBS and incubated for 2 h at room 20 
temperature. Coverslips were washed 3 times with PBS and mounted onto slides 21 
using Fluoromount G (Southern Biotech, Alabama, US). Images were acquired 22 
either using a wide-field deconvolution microscope DeltaVision (Applied 23 
Precision Inc., Issaquah, US) or an EVOS-fl inverted digital microscope (Life 24 
technologies, Paisley, UK). Relative protein levels or co-distribution were 25 
analysed and quantified using Image J (NIH, Bethesda, US). 26 
 27 
2.2.3.3 Cell immunofluorescence using Affimers 28 
Non-permeabilised LOX-1 expressing HEK-293-T cells were incubated with 29 
increasing concentrations of Alexafluor-488 labelled Affimer in DMEM on ice for 30 
2 h. To assess inhibition of oxLDL uptake, HEK293T cells pre-incubated with 31 
Affimer as described were then incubated with DiI labelled oxLDL. After washing 32 
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steps with PBS, cells were fixed with 3% (w/v) PFA and coverslips mounted as 1 
previously described. 2 
 3 
2.2.4 Animal studies 4 
 5 
2.2.4.1 Animal husbandry 6 
All mice were housed in individually ventilated cages at no more than 5 per unit. 7 
Animals only shared a cage with siblings of the same sex. The complex lighting 8 
was on a ‘fade up-fade down’, 12 h light and 12 h dark cycle from 0630 to 1830. 9 
Room temperature was 21°C +/- 2°C. Standard chow feed (Rat and Mouse No.1 10 
Maintenance; Special Diet Services, Essex, UK) and water were available ad 11 
libitum. Mice were checked upon daily. Breeding cages were set up with 1 male 12 
and 2 females over the age of 8 weeks. Pups were weaned at 18 days and ear 13 
notched for identification thereafter. Stringent records were kept of husbandry 14 
and experimental procedures. Any mice displaying stunted development or overly 15 
aggressive behaviour were excluded from experiments. Mice were fed with 0.2% 16 
cholesterol Western diet (Special Diet Services, Essex, UK) for 12 weeks from 8 17 
weeks of age. Before 8 weeks old, they were fed standard chow (Special Diet 18 
Services, Essex, UK). Feed was available ad libitum and animals were weighed 19 
weekly. 20 
 21 
2.2.4.2 DNA extraction for genotyping 22 
Ear notches were taken from mice in accordance with Home Office regulations. 23 
DNA from ear notches were extracted using MyTaq Extract PCR kit (Bioline, 24 
London, UK) according to the manufacturer’s instructions. Briefly, 20 μl of buffer 25 
A, 10 μl of buffer B and 20 μl deionized water were added and vortexed. The 26 
mixture was incubated at 75°C for 5 min followed by further incubation at 95°C 27 
for 10 min. The mixture was then spun down for 1 min at top speed. The extracted 28 
DNA in the supernatant was diluted 1:9 with deionized water and used for PCR 29 
analysis.  30 
 31 
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2.2.4.3 Genotype analysis using polymerase chain reaction (PCR) 1 
PCR amplification of DNA was carried out using MyTaq HS Red mix (Bioline, 2 
London, UK) according to manufacturer’s guidelines. For LOX-1 and APO-E 3 
PCR, 1 μl of DNA was mixed on ice with 12.5 μl MyTaq HS Red mix, 0.5 μl of 4 
20mM primers (table 2.3) and top it up to 25 μl with deionized water. PCR was 5 





Table 2.1. Primer sequences for DNA genotyping 11 
LOX-1  
Forward  5’- CGC CAA CCA TGG CTA TGG GAG AAT GG -3’  
Reverse  5’- CAG CGA ACA CAG CTCCGT CTT GAA GG -3’  
APO-E   
Common  5’- GCC TAG CCG AGG GAG AGC CG -3’  
Wild-type reverse  5’- TGT GAC TTG GGA GCT CTG CAG C -3’  
Mutant reverse  5’- GCC GCC CCG ACT GCA TCT -3’  
 12 
Electrophoresis of DNA samples from PCR was carried out using 1-2.5% (w/v) 13 
agarose gels containing 1 μg/ml ethidium bromide in 0.5X TAE buffer (2 mM Tris, 14 
1 mM acetic acid, 0.5 mM EDTA, pH 8) or 0.5X TBE buffer (45 mM Tris, 45 mM 15 
boric acid, 1 mM EDTA, pH 8). Gels were run in 0.5X TAE or 0.5X TBE buffer at 16 
100 V for ~1 h. DNA was visualised in a G:BOX XT4 Chemi imaging workstation 17 
(Syngene, Cambridge, UK).  18 
 19 
2.2.5 Animal experimental procedures 20 
 21 
2.2.5.1 Glucose tolerance test 22 
Mice were fasted from feeding for 16 h.  A single tail wound was then created 23 
using a 20 gauge needle and a blood drop put onto a glucose test-strip (SD 24 
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Codefree glucose test strips, SD biosensor, South Korea) to obtain a baseline 1 
fasting glucose measurement using an Accu-Check Aviva Nano system 2 
(Hoffmann-La Roche, Basel, Switzerland). 1 mg per g total body weight of 10% 3 
sterile glucose solution was then injected intraperitoneally and further blood 4 
glucose measurements were obtained by expressing blood from the wound at 5 
30, 60, 90 and 120 min. Mice were monitored for 1 h post procedure. 6 
 7 
2.2.5.2 Insulin tolerance test 8 
Mice were fasted from feed for 4 h and a baseline fasting glucose measurement 9 
was taken as described above. 0.75 IU/kg sterile actrapid insulin (0.1 IU/ml in 10 
1XPBS) was then injected intraperitoneally and further blood glucose 11 
measurements were obtained by expressing blood from the tail wound at 30, 60, 12 
90 and 120 min. During the procedure mice exhibiting signs of severe 13 
hypoglycaemia or giving blood glucose readings of <1.5 mmol/L were treated with 14 
1 mg per g total body weight of 10% glucose solution intraperitoneally and 15 
excluded from the experiment. Mice were monitored for 1 h post procedure. 16 
 17 
2.2.5.3 Induction and maintenance of anaesthesia 18 
Mice were placed in an anaesthetic chamber. 2 L/min oxygen and 5 L/min 19 
isoflurance were administered to achieve full anaesthesia (unresponsive to 20 
stimulus, reduced respiratory rate). Mice were then transferred to a warmed 21 
operating table (37°C) and anaesthesia maintained by administering oxygen and 22 
isoflurane, both at 2L/min via a veterinary face mask throughout the procedure. 23 
On completion, mice were given 0.25 mg/kg of buprenorphine (Vetergesic, 24 
Reckitt Benckiser Healthcare, Hull, UK) and a 500 µl bolus of 0.9% saline 25 
intraperitoneally. The isoflurane was withdrawn and oxygen continued at 2 L/min 26 
for 1-2 min. Mice were then transferred to a pre-warmed (37°C) recovery cage 27 
and monitored every 30 minutes until full recovery from anaesthesia. 28 
 29 
2.2.5.4 Femoral artery wire injury 30 
At 16 weeks of age (8 weeks of Western diet), anaesthesia was induced and 31 
maintained as described above. The mice were placed supine with the legs 32 
extended, abducted and externally rotated. Positioning was secured using 33 
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surgical tape. The left leg and lower abdomen was initially shaved. To optimize 1 
hair removal, veet cream was then applied to the area and removed after 2 min 2 
using a cotton bud. Skin was then cleansed using 70% (v/v) ethanol solution. The 3 
procedure was performed with the aid of a surgical microscope (Carl Zeiss, 4 
Thornwood, USA) under the appropriate magnification (~X10 à X20). A 5 
longitudinal groin incision was made, crossing the inguinal ligament. The femoral 6 
vessels are exposed at two sites: immediately distal to the inguinal ligament and 7 
distal to the epigastric artery. The segment of femoral artery between the origins 8 
of the epigastric and saphenous arteries was dissected free from the 9 
neurovascular bundle and encircled with a loosely tied 8/0 vicryl suture (Ethicon, 10 
Somerville, USA) (Figure 2.3). The femoral artery was clamped immediately 11 
distal to the inguinal ligament and an arteriotomy is made 1 mm distal to the origin 12 
of the epigastric artery. A 0.25 mm diameter angioplasty guidewire was 13 
introduced via the arteriotomy and the clamp released. The guidewire was then 14 
advanced and withdrawn 3 times to the level of the aortic bifurcation. The wire 15 
was then removed and the arteriotomy site is ligated using the 8/0 vicryl suture. 16 
The skin incision was closed using a continuous 6/0 vicryl suture. Anaesthesia 17 
was then completed as described above and the mice are placed in a pre-warmed 18 
(37°C) recovery cage and monitored every 30 minutes until full recovery from 19 
anaesthesia. 20 
 21 
2.2.5.5 Osmotic pump implantation 22 
Alzet ® osmotic pumps (Model 1004, Charles River Laboratories, Wilmington, 23 
USA) were pre-loaded with 100 µl of 1mg/ml LOX-1 specific affimer in 1XPBS in 24 
accordance with manufacturer’s instructions. At 12 and 16 weeks of age (4 weeks 25 
and 8 weeks of western diet), anaesthesia was induced and maintained as 26 
described above. At 12 weeks of age, mice were positioned prone and an area 27 
extending from the base 2cm caudally was shaved and cleansed. A 1 cm 28 
longitudinal incision was made in the midline, immediately caudal from the base 29 
of the skull. A closed artery forcep was advanced bluntly within the subcutaneous 30 
layer to create a tract extending to the right flank. An osmotic pump containing 31 
1mg/ml LOX-1 specific affimer in 1 X PBS was advanced in to the tract to the 32 
right flank using the artery forcep. The wound was closed using a continuous 6/0 33 
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vicryl suture and the mice recovered as described above. At 16 weeks of age, 1 
the procedure was repeated by re-opening the same incision, but by placing the 2 
second osmotic pump in the contralateral flank. The skin incision was closed and 3 






Figure 2.3. Anatomy of femoral artery wire injury. Demonstrating the basic 10 
anatomical landmarks for femoral artery wire injury. 11 
 62 
2.2.5.6 Tissue harvesting 1 
Isofluorane (CBS, University of Leeds) anaesthesia was induced and a cardiac 2 
puncture technique was performed to withdraw blood. Mice were laid on their 3 
back, and using a 1 ml syringe and a 22-gauge needle, needle was inserted 4 
perpendicular to chest wall, straight to the apex of the heart in the left ventricle. 5 
Blood was slowly withdrawn by gently pulling back on the plunger to obtain the 6 
maximum amount of blood available. Blood was transferred to heparin-coated 7 
tubes and immediately placed on ice. This was followed by performing a midline 8 
laparotomy. The abdominal contents were displaced to the right. 5 ml of PBS was 9 
slowly perfused into the left ventricle to flush out any remaining blood. Using the 10 
same needle, 10 ml of 4% (w/v) PFA was perfused to achieve fixation. Following 11 
fixation, organs were dissected out and placed in to cassettes in 4% (w/v) PFA 12 
for further processing. 13 
 14 
2.2.5.7 Vascular harvest 15 
Aorta 16 
The aorta was exposed from the heart to the iliac bifurcation and carefully 17 
dissected from the surrounding tissue. Minor branching arteries were cut off and 18 
the adventitia is removed as much as possible in situ, being careful not to tear 19 
the aorta. The aorta was divided at its root and placed in a 1.5 ml Eppendorf tube 20 
on its side, half full with 4% (w/v) PFA, allowing the aorta to straighten and 21 
avoiding folding. The aorta was then prepared under microscopy by stripping 22 
away the residual fat and adventitia. It was then opened longitudinally along its 23 
ventral surface and following the inner curvature of the aortic arch. Oil red-O 24 
staining of the aorta was then carried out to visualize lipid- and fat-enriched 25 
plaques or lesions. 26 
 27 
Carotid artery 28 
The midline thoracotomy incision was extended to open the ventral surface of the 29 
neck, exposing the salivary glands. Glandular tissue and surrounding fat was 30 
moved laterally by blunt dissection and the trachea is dissected out to the level 31 
of the larynx to expose the oesphagus and common carotid arteries. The 32 
oesophagus and carotid arteries were taken en-bloc as high as possible to the 33 
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level of the jaw. If taken high at the level of the jaw, the carotid bifurcation should 1 
be within the distal third of the specimen. 2 
 3 
Femoral artery 4 
The iliac bifurcation was left intact after harvesting of the aorta. The hind-limbs 5 
were opened along their medial surface (anterior when mouse is in position as 6 
described in 2.2.7) from the pelvis to the level of the knee. The femoral vessels 7 
were dissected out along with surrounding musculature to the level of the iliac 8 
bifurcation, which was kept intact. The result should be a single specimen 9 
comprising of the iliac bifurcation and both femoral arteries to the level of both 10 
distal saphenous arteries. 11 
 12 
2.2.6 Histological preparation 13 
Histological preparation was carried out in the following steps: 14 
• Fixation (Described in 2.2.7) 15 
• Processing 16 
• Embedding 17 
• Microtomy 18 
• Staining 19 
• Analysis 20 
 21 
2.2.6.1 Processing 22 
Due to the hydrophobic nature of embedding paraffin, specimens must be 23 
chemically dehydrated and cleared of lipids to allow penetration of paraffin during 24 
the embedding process. Fixed harvested tissues within cassettes were sent for 25 
processing to the histopathology lab at St. James University Hospital (University 26 
of Leeds, UK). Processing was carried out and data collected by an automated 27 
imaging system. 28 
 29 
2.2.6.2 Embedding 30 
The embedding station was warmed and tissue cassettes were placed in a 31 
container of liquid paraffin for 30 min. Each organ / tissue element was placed an 32 
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appropriate mould in the desired orientation and the mould filled with liquid 1 
paraffin to half full. The mould was then placed on a cold (4°C) surface to solidify 2 
the paraffin and hold the specimen in the desired position. An embedding ring 3 
was then placed on top of the mould and the paraffin in poured in to reach the 4 
top of the ring. The mould was then placed on the cold surface for 20-30 min to 5 
allow the entire block to solidify. Once this has occurred, the ring can be gently 6 
removed from the mould along with the paraffin block for microtomy or storage. I 7 
recommend storage at room temperature as cutting the block in preparation for 8 
microtomy may lead to cracking and potential damage of the specimen if storage 9 
has been stored at 4°C. If this does happen, the block must be handled carefully 10 
and re-embedded. 11 
 12 
2.2.6.3 Microtomy 13 
A water bath of ddH2O at 45-50°C was prepared. At room temperature, the block 14 
was cut on its distal surface in to a trapezium as shown in Figure 2.4. The block 15 
was then placed face-down in ice for 20-30 min. Instruments used for microtomy 16 
(fine forcep, small paint brush) should also be placed in the ice for this time. The 17 
ring was placed in the microtome (Leica Biosystems, Germany) and a microtome 18 
blade (S35: 80mm / 8mm / 35°, Feather, Japan) was loaded. 5 µm sections were 19 
cut. At intervals of 100 µm, a ribbon of 8-10 slices was placed in the water bath 20 
and transferred to an uncoated microscopy slide for viewing. Once the desired 21 
level was reached (carotid bifurcation, femoral bifurcation, femoral artery) (Figure 22 
2.5), the process was repeated using a poly-l-lysine-coated microscopy slide. The 23 
slide was labelled and set aside in an upright position in a drying rack before 24 













Figure 2.4. Orientation of specimen in embedding paraffin. The trapezium 5 
cut around the specimen is such that the short edge represents the anterior 6 













Figure 2.5. Microtomy of carotid and femoral arteries: anatomical 5 
landmarks. (A) Carotid artery: (i) common carotid artery (CCA), (ii) bifurcation of 6 
common carotid artery, (iii) internal carotid artery with plaque (ICA), external 7 
carotid artery(ECA). (B) Femoral artery: (i) saphenous artery (SA) and epigastric 8 
artery (EA), (ii) ligature (L) and common femoral artery with degree of neointimal 9 





2.2.7 Histological staining 2 
 3 
2.2.7.1 Oil red O staining 4 
Stock oil red O stain was prepared by dissolving 0.5 g of of oil red O in 100 ml of 5 
isopropanol while gently heating in a water bath. The solution was covered from 6 
light. Prior to use, 30 ml of stock stain was diluted in 20 ml of ddH2O and allowed 7 
to stand for 10 min before being filtered. The prepared aorta was placed in 60% 8 
(v/v) isopropanol for 5 min. It was then placed in an Eppendorf tube containing oil 9 
red O and covered from light. The tube was then placed in a 50 ml falcon tube 10 
and put on a rolating platform for 1 h. The aorta was then removed from the oil 11 
red O and washed in 60% (v/v) isopropanol followed by ddH2O. The stained aorta 12 
was then mounted on a 64 mm microscope slide for viewing and analysis. 13 
 14 
2.2.7.2 Elastin staining with Miller and counter staining with Van Gieson 15 
The following solutions are required: 16 
• Xylene: 100% solvent (Sigma or ThermoFisher). NB: toxic, handle under 17 
fume hood. 18 
• Ethanol 100% (Sigma). 19 
• Potassium Permanganate KMnO4 0.5 % (Product Number: 223468, 20 
Sigma). Prepare by dissolving 2.5 g in 500 ml of ddH2O. Store in bottle 21 
protected from light at room temperature. Prepare fresh when it changes 22 
colour from dark purple to brown. 23 
• 2% Oxalic Acid (Product Number: 75688, Sigma). To prepare 2% solution 24 
dissolve 8 g of powder in 400 ml of ddH2O. Store in bottle protected from 25 
light at room temperature. Prepare fresh once becoming non-clear (slightly 26 
brown from bleaching after KMnO4). 27 
• Miller stain 100% solution (Product number: RHS-235 500ml, Cell Path). 28 
• Van Gieson stain made by diluting ready bought Van Gieson solution with 29 
picric acid to achieve bright orange/red coloured dye. Store in bottle 30 
protected from light at room temperature. 31 
•  DPX mountant (Product number: 06522, Sigma). 32 
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 1 
Before staining slides were dried in oven (37°C) overnight. Staining was carried 2 
out in fume hood to avoid inhalation of harmful solvents. Slides were placed in a 3 
rack for staining; each rack holding 25 slides. Chemicals and staining solutions 4 
were placed in jars designed for holding and submerging racks. Each rack was 5 
moved through 3 consecutive jars of deparaffinising xylene, for 3 min at a time, 6 
followed by 3 consecutive jars of 100% ethanol, also for 3 min each. The rack 7 
was then submerged briefly in a basin of tap-water to wash off ethanol. The rack 8 
was then washed briefly in ddH2O before being placed in a covered jar of 0.5% 9 
(w/v) KMnO4 for 10 min. The rack was washed in tap-water, followed by ddH2O 10 
as before. The sections at this point were expected to turn brown in colour. The 11 
rack was then placed in a jar of 2% oxalic acid until sections turned translucent / 12 
white (1-2 min). The rack was then washed in tap-water, followed by ddH2O and 13 
then placed in 100% ethanol for 5 sec before being placed in a covered jar of 14 
Miller stain. The racks were left in Miller stain for 1 h. They can be left for longer, 15 
however the time in Miller stain should remain consistent across all specimens 16 
throughout the experiment. Once Miller staining was complete, the rack is then 17 
placed in 6 consecutive jars of re-used 100% ethanol ranging from the most 18 
contaminated with Miller stain (dark blue) to the cleanest (colourless). The rack 19 
was then placed in tap-water followed by ddH2O, followed by a covered jar of Van 20 
Gieson stain for 20 min. The rack was the washed in 2 consecutive jars of ddH2O. 21 
The racks were then dried by tapping on tissue paper and placed in an oven at 22 
70°C until completely dry (normally 20-30 min). The rack was then placed in 3 23 
consecutive jars of xylene for 3 min each, leaving the rack in the final jar of xylene 24 
while each slide is individually mounted on 64 mm coverslips using DPX mounting 25 
solution. Slides were left to dry in the fume hood for 1-2 h before analysis or 26 
storage.  27 
 28 
2.2.7.3 Haematoxylin and Eosin staining 29 
The following solutions are required: 30 
• Xylene: 100% solvent (Sigma or ThermoFisher). NB: toxic, handle under 31 
fume hood. 32 
• Ethanol 100% (Sigma). 33 
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• Scott’s tap water 1 
o In 1 L of deionised H2O dissolve: 2 
i.  2 g NaHCO3 3 
ii. 20 g MgSO4 4 
• 1% acid alcohol 5 
• 1ml concentrated HCl in 99 ml 70% (v/v) ethanol 6 
• Haematoxylin solution (Sigma). 7 
• Eosin solution (Sigma 8 
• DPX mountant (Product number: 06522; Sigma). 9 
 10 
Before staining slides were dried in oven (37°C) overnight. Staining was carried 11 
out in fume hood to avoid inhalation of harmful solvents. Slides were placed in a 12 
rack for staining; each rack holding 25 slides. Chemicals and staining solutions 13 
were placed in jars designed for holding and submerging racks. Each rack was 14 
moved through 3 consecutive jars of deparaffinising xylene, for 3 min at a time, 15 
followed by 3 consecutive jars of 100%, 95% and 95% ethanol respectively, also 16 
for 3 min each. The rack was then submerged briefly in a basin of tap-water to 17 
wash off ethanol. The rack was then placed in pre-filtered haematoxylin solution 18 
for 3-5 min, followed by tap-water and ddH2O to wash. The rack is then dipped 19 
twice in 1% acid alcohol. At this point it is important to check under microscope 20 
that haematoxylin has not been washed out. The rack was then washed in tap- 21 
water for 1 min, followed by Scott’s tap water for 1-3 min (until sections turn blue). 22 
The rack was then washed in tap-water followed by ddH2O (removes alkali from 23 
Scott’s tap water otherwise eosin will not stain). The rack was then placed in 5% 24 
eosin solution for 5 min, followed by tap-water for 5 min and finally washed in 25 
ddH2O. The rack was then placed in 3 consecutive jars of 100% ethanol for 3 min 26 
each, followed by 3 consecutive jars of xylene also for 3 min each, leaving the 27 
rack in the final jar of xylene while each slide is individually mounted on 64mm 28 
coverslips using DPX mounting solution. Slides were left to dry in the fume hood 29 




2.3 Histological analysis 1 
All histological analysis was performed using an Olympus BX41 microscope 2 
(Olympus, Japan) in conjunction with Image-Pro Plus software (Media 3 
Cybernetics, USA). To measure total aortic plaque, first a line was drawn around 4 
the aorta ensuring that arch and distal branches are not included. Total plaque 5 
area was divided over the aortic surface area for the final % value (figure 2.6). 6 
Cross-sectional plaque area at the carotid bifurcation and common femoral artery 7 
were measured as described in Figure 2.6. For the measurement of % neointimal 8 
hyperplasia (NIH), the adventitia was the most reliable landmark for the 9 
outermost layer of the artery and was used in a modified calculation to include 10 
the medial and neointimal layers: 11 
NIH % = (adventitial area – lumen area) / adventitial area 12 
2.4 Statistical analysis 13 
This was performed using the unpaired two-tailed Student’s t-test for 2 groups or 14 
one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc test for 15 
multiple comparisons using GraphPad Prism software (La Jolla, CA, US). 16 
Significant differences between control and test groups were evaluated with p 17 
values less than 0.05 (*), 0.01 (**), 0.001 (***) and 0.0001 (****) indicated on the 18 
graphs. Error bars in graphs denote ± SEM (Standard error of mean). 19 
 20 
2.5 Home Office License and ethical approval for animal studies 21 
All animal studies were carried out by researchers holding a Home Office 22 
Personal License and under a Home Office Project License held by Professor 23 
Stephen Wheatcroft (Project License number: P144DD0D6). Ethical approval 24 
was granted by the University of Leeds Ethics Committee.  25 
The severity of femoral artery wire injury and osmotic pump implantation were 26 




Figure. 2.6. Measuring atherosclerotic plaque area. (A) Total plaque area (%) 3 
is measured as plaque area (red) divided by total aortic surface area (area within 4 
green line). The measurement is repeated by 2 independent investigators and 5 
the final result is taken as the mean. (B) Total plaque / NIH area is calculated 6 
from a cross-section of the vessel. IEL; internal elastic lamina. OEL; outer elastic 7 





CHAPTER 3 1 
CELLULAR STUDIES ON LOX-1 FUNCTION 2 
 3 
3.1 Introduction 4 
Monoclonal antibodies are the most commonly used affinity agents in biomedical 5 
research. They play an important role in the treatment of a range of pathologies 6 
including autoimmune, cardiovascular and infectious diseases, cancer and 7 
inflammation. Despite their widespread use, there are a number of known 8 
drawbacks including high molecular weight, limited tissue penetration, instability, 9 
high production cost, requirement for large doses, and potential immunogenicity 10 
(Chames et al., 2009). Non-antibody synthetic protein scaffolds are low molecular 11 
weight molecules and affinity tools which mimic the molecular recognition 12 
properties of antibodies (Škrlec, Štrukelj and Berlec, 2015). They can be 13 
expressed in bacterial cell culture; reducing production costs, and are 14 
thermostable at a wide range of temperatures. The Affimer is a small 15 
(approximately 100 amino acid) synthetic protein scaffold which has been 16 
developed at the University of Leeds by McPherson and Tomlinson (Tiede et al., 17 
2014). Affimers are based on plant-derived phytocystatin sequence. They are 18 
monomeric, highly soluble, thermostable at temperatures up to 101°C and can 19 
be expressed in bacterial cell culture. Studies have demonstrated specific binding 20 
of Affimers to targets such as vascular endothelial growth factor receptor and 21 
tenascin C in cells, fixed tissue and in vivo (Tiede et al., 2017). Affimers, as part 22 
of a wider spectrum of synthetic protein scaffolds, have potential as novel agents 23 
in diagnostics and therapeutics in cardiovascular disease, given their ability to 24 
bind a wide range of targets.  25 
The LOX-1 scavenger receptor is implicated in the development of 26 
atherosclerosis partly due to its role in macrophage binding and internalization of 27 
oxLDL (Chistiakov, Orekhov and Bobryshev, 2016). This leads to the formation 28 
of foam cells which accumulate within the sub-endothelial layer, triggering an 29 
inflammatory cascade resulting in atherosclerotic plaque formation (Chistiakov, 30 
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Orekhov and Bobryshev, 2016). LOX-1 is a membrane protein consisting of 4 1 
domains; a short N-terminal cytoplasmic, a transmembrane, a connecting neck, 2 
and a lectin-like domain at the C terminus which binds oxLDL (Zani et al., 2015). 3 
Blocking LOX-1 in vitro has been shown to reduce the apoptotic effects of oxLDL 4 
co-incubation while transgenic animal studies have shown that LOX-1 knockout 5 
attenuates the development of atherosclerosis (Mehta Jawahar et al., 2007; Li et 6 
al., 2003). Studies investigating the use of anti-LOX-1 antibody in vivo report 7 
significant reductions in neointimal hyperplasia post balloon carotid artery injury 8 
and myocardial infarct size post coronary artery ligation (Hinagata et al., 2006; Li 9 
et al., 2002b). Additional reported effects of anti-LOX-1 antibody include reduced 10 
mesenteric artery lipid deposition in hypertensive rats and the attenuation of renal 11 
vascular fibrosis in obese diabetic hypertensive rats (Nakano et al., 2010; 12 
Dominguez et al., 2008).  13 
Phage-display screening has identified 5 isoforms of LOX-1 specific Affimer. 14 
Affimer binding to the LOX-1 SR has the potential to attenuate the formation of 15 
atherosclerosis by interfering with the internalization of oxLDL in vascular cells. 16 
The aim of this chapter is to quantify Affimer-LOX-1 binding and investigate their 17 
effect on oxLDL internalization in vitro. 18 
 19 
3.2 Results 20 
3.2.1 Expression, purification of LOX-1-specific Affimers 21 
As previously discussed, one potential advantage of using recombinant proteins 22 
as antibody mimetics is that they can be expressed in bacterial cell culture. The 23 
advantages of Escherichia coli (E. coli) as a host organism in recombinant protein 24 
technology include unparalleled fast growth kinetics, the ease at which high cell 25 
density cultures can be achieved, and the speed at which plasmid DNA 26 
transformation can be performed (Rosano and Ceccarelli, 2014). Affimer proteins 27 
which bind specifically to the LOX-1 SR have been isolated using phage display 28 
techniques prior to the undertaking of this research. 29 
Plasmid DNA coding for 5 distinct LOX-1-specific Affimer isoforms were 30 
transfected in to competent E. coli cells (BL21*DE3) using a rapid transformation 31 
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protocol, following which the expression and purification of Affimer protein is 1 
carried out as per the protocol outlined in materials and methods. The Affimer 2 
scaffold includes a polyhistidine tag allowing for immobilised metal affinity 3 
chromatography to be carried out using immobilized nickel-nitrilotriacetic acid (Ni- 4 
NTA) agarose resin (Figure 3.1A). This method of protein purification is well 5 
described (Bornhorst and Falke, 2000). Briefly, the imidazole ring within the 6 
histidine residue readily forms coordination bonds with the immobilized Ni-NTA 7 
resin. The bacterial cell lysate is incubated with the immobilized Ni-NTA resin 8 
leading to the chelation of His-tagged Affimers to the resin. Unbound or weakly 9 
bound non-specific protein is washed from the resin in multiple repeated steps 10 
until the optical density at 280nm is undetectable. The desired Affimer protein is 11 
then eluted from the column by the addition of an imidazole-based elution buffer 12 
which competitively binds to the resin and cleaves off the his-tagged Affimers. 13 
The Affimer was eluted in low volume aliquots (100 µl) to maintain protein 14 
concentration by avoiding dilution. The purity and concentration of the protein 15 
sample is then determined using SDS page electrophoresis against bovine serum 16 
albumin (BSA) controls (Figure 3.1A, B, C). A 50 ml culture volume would reliably 17 
yield at least 1 mg of purified Affimer protein.  18 
 19 
3.2.2 Labelling of LOX-1 Affimer 20 
Binding of fluorescent tags to molecules of interest to gain information from cells, 21 
fixed tissue and living organisms is a widely accepted and enormously important 22 
tool in biomedical research. The lack of disulphide bonds in the Affimer allows 23 
directed introduction of a cysteine (cys) residue for site specific chemical 24 
modification, including addition of a single biotin or fluorophore. Immediately 25 
following elution, Affimers were labelled with Alexafluor-488 or biotin at room 26 
temperature. Successful conjugation is determined by either biotinylation ELISA 27 
(Figure 3.2) or by absorbance at 488 nm following SDS-PAGE electrophoresis 28 
(Figure 3.3). An estimation of binding efficiency is calculated by comparing the 29 
internal density of a band at 11-14 kDa after excitation at 488 nm against the 30 
internal density of the same band stained with Coomassie blue. The binding 31 
efficiency of cys-tagged Affimers to Alexafluor-488 is approximately 1:1, showing 32 
maximal efficiency of labelling. 33 
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 1 
Figure 3.1. Expression and purification of LOX-1-specific Affimer H1. (A) 2 
LOX-1-specific Affimers are expressed in E. coli BL21*DE3 cells. After cell lysis, 3 
and purification using Ni-NTA resin with washes and elution with imidazole (see 4 
Materials and Methods). Washing steps remove non-specifically bound proteins 5 
(Wash 1 and Wash 10), followed by elution using imidazole buffer (elutions 1-8). 6 
(B) Comparison of eluted H1 Affimer to BSA using SDS-PAGE and Coomassie 7 
staining. (C) The concentration of eluted H1 Affimer was compared to BSA 8 




Figure 3.2. Fluorescent labelling of LOX-1-specific H1 Affimer. (A) Gel 3 
electrophoresis of Alexafluor-488-labelled LOX-1 H1 Affimer prepared as 4 
described in Materials and Methods. (B) Determination of efficiency of Alexafluor- 5 
488 conjugation to H1 Affimer using excitation at 488 nm and emission at 520 nm 6 
followed by digital imaging. (C) By comparing protein level and measured 7 
fluorescence, the binding efficiency is likely to be close to 1:1. Error bars denote 8 










Figure 3.3. Biotinylation of LOX-1-specific H1 Affimer. Biotinylated Affimer 8 
bound to an ELISA plate was probed with streptavidin-HRP and absorbance at 9 
492 nm was measured, to check for biotinylation. Error bars denote ±SEM (n=3). 10 






3.2.3 Affinity and cross reactivity studies using biotinylated LOX-1 Affimers 1 
Prior to embarking on cell-based studies, the affinity of LOX-1 Affimers to the 2 
LOX-1 protein was measured using an ELISA technique. All 5 species of LOX-1 3 
Affimers were biotinylated and biotinylation confirmed by biotinylation assay. The 4 
affinity of LOX-1 Affimers to both human and murine LOX-1 is important for 5 
planned future in vitro and in vivo murine studies. The opportunity was taken to 6 
measure affinity to both human and murine extracellular domain LOX-1 in a 7 
cross-reactivity study with the added aim of identifying a single isoform to take 8 
forward in to such studies.  9 
Two separate ELISA plates were coated overnight with increasing concentrations 10 
of either human or mouse soluble LOX-1 protein. BSA was added to each row as 11 
a negative control and a yeast-small ubiquitin-like modifier protein (yeast SUMO) 12 
specific Affimer was used as a further negative control in a separate row on each 13 
ELISA plate. All 5 species of LOX-1-specific Affimer exhibited affinity for human 14 
LOX-1 protein. A1, B1 and H1 Affimers tended to perform better compared with 15 
A3 and G1 however the difference was not statistically significant (Figure 3.4A). 16 
On the mouse soluble LOX-1-coated plate, both B1 and H1 exhibited a significant 17 
affinity compared to the control (yeast SUMO Affimer) (Figure 3.4B). By 18 
comparing the affinity of each Affimer species to human and mouse LOX-1, we 19 
found the only species which has an equal affinity for human and mouse LOX-1 20 
was Affimer H1 (Figure 3.5). Given this result, the H1 Affimer was taken forward 21 




Figure 3.4. Cross-reactivity of LOX-1-specific Affimers for human and 2 
mouse soluble LOX-1 proteins. Human and mouse soluble LOX-1 were probed 3 
with different biotinylated Affimers such as (A) A1, (B) A3, (C) B1, (D) G1, (E) H1, 4 
or (F) negative control Affimer for yeast SUMO (YS) and bound Affimer was 5 
detected using streptavidin-HRP. At higher concentrations (1 mg/ml) of LOX-1, 6 
there was no significant difference of LOX-1 H1 Affimer to discern between 7 
human and mouse LOX-1. Error bars denote ±SEM (n=3). NS; not significant. 8 
p<0.05 (*), p<0.01 (**), p<0.0001 (****). YS; biotinylatyed yeast sumo specific 9 
affimer. hLOX-1; human soluble LOX-1. mLOX-1; mouse soluble LOX-1. 10 





Figure 3.5. Relative affinity of LOX-1-specific Affimers for human and 4 
mouse soluble LOX-1. Relative affinities of LOX-1-specific Affimers are 5 
compared for (A) human soluble LOX-1, or (B) mouse soluble LOX-1. Error bars 6 
denote ±SEM (n=3). NS; not significant. p<0.001 (***), p<0.0001 (****). YS; 7 




3.2.4 LOX-1 Affimers bind to LOX-1 in vitro 2 
 3 
3.2.4.1 Validation of tetracycline-inducible LOX-1 expression in HEK-293T 4 
cells 5 
LOX-1 expression itself is associated with increased programmed cell death 6 
(apoptosis), making the study of its function challenging (Li and Mehta, 2009). A 7 
tetracycline-inducible expression system in human embryonic kidney cells 8 
(HEK293T) has been created to facilitate experiments studying the functional role 9 
of LOX-1 (Abdul-Zani (2017) PhD thesis). The Flp-InTM T-RexTM system uses 10 
the flippase recognition target site for integration of the LOX-1 cDNA by flippase 11 
recombinase. LOX-1 transgene expression is tightly controlled by the tetracycline 12 
repressor which blocks gene transcription by binding to two tetracycline operator 13 
sequences upstream of the gene of interest. Utilizing this system enables control 14 
of the timing of gene expression by eliminating variability in transgene expression 15 
levels caused by genome specific variability (Thomas et al., 2004). Previous work 16 
has demonstrated that LOX-1 expression peaks at 16 hours’ incubation with 1 17 
µg/ml tetracycline in standard Dulbecco's Modified Eagle Medium (DMEM) 18 
(Abdul-Zani (2017) PhD thesis). For negative control purposes, a colony of 19 
HEK293T cells were transfected with an empty plasmid, known as “empty 20 
vector”. 21 
Tetracycline-induced expression of LOX-1-FLAG in HEK-293T cells was 22 
validated before embarking on LOX-1-Affimer studies. Permeabilised HEK293T 23 
cells were fixed and stained with sheep anti-LOX-1 (Figure 3.6A, 3.6B). A 24 
proportion of induced cells were lysed for Western blot analysis. Cell lysates from 25 
induced LOX-1 and empty vector HEK-293T cells were probed using sheep anti- 26 
LOX-1 using immunoblotting: the data confirmed tetracycline-inducible 27 







Figure 3.6. LOX-1-FLAG expression in tetracycline-inducible HEK293T cell 3 
line. (A) Tetracycline-induced LOX-1-FLAG expressing and empty vector 4 
(control) HEK293T cells are probed with sheep anti-LOX-1 antibody (green) by 5 
immunocytochemistry. (B) Quantification of relative LOX-1 levels by estimation 6 
of fluorescence pixel intensity. (C)  HEK-293T cell lysates probed with sheep anti- 7 
LOX-1 antibody by immunoblotting. (D) Quantification of immunoblot data and 8 
relative LOX-1 expression levels. Error bars denote ±SEM (n=3). NS; not 9 
significant. p<0.01 (**), p<0.0001 (****). EV; empty vector. Tet; tetracycline. AUC; 10 
area under curve. Statistical test: One-way ANOVA. 11 
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3.2.4.2 Immunofluorescence studies using alexafluor-488 tagged LOX-1 1 
Affimers 2 
To demonstrate the ability of LOX-1 Affimers to bind LOX-1 in vitro, Alexafluor- 3 
488-labelled Affimers were created and validated as described above. On 4 
coverslips, induced HEK-293T cells were incubated with excess Alexafluor-488- 5 
labelled LOX-1-specific Affimer in low serum medium on ice for 2 h. Cells were 6 
fixed and processed for immunofluorescence microscopy (Figure 3.7). The data 7 
demonstrates Affimer-LOX-1 binding in LOX-1 expressing cells while no signal is 8 
seen in empty vector cells (Figure 3.7A). To rule out non-specific binding in the 9 
LOX-1 expressing cells, an excess of recombinant soluble LOX-1 was added 10 
alongside the Affimer. The soluble LOX-1 competitively binds the LOX-1 Affimers. 11 
Quantification of microscopy data shows a degree of non-specific effects in the 12 
empty vector and soluble LOX-1 co-incubated controls compared with cells 13 
without Affimer incubation (p<0.05), however a much greater effect is 14 
demonstrated in LOX-1-expressing cells incubated with fluorescent LOX-1- 15 




Figure 3.7. Fluorescent labelled LOX-1-specific Affimer binding to LOX-1- 3 
expressing cells. (A) Fluorescent LOX-1-specific Affimer tagged with Alexafluor- 4 
488 incubated at 100 mg/ml with tetracycline-induced HEK293T cells (EV 5 
control). Soluble LOX-1 is added in >10-fold excess to competitively bind Affimer 6 
and block binding to cellular LOX-1. (B) Quantification of labelled anti-LOX-1 7 
Affimer binding by counting arbitary fluorescence pixel intensity. Error bars 8 
denote ±SEM (n=3). p<0.05 (*), p<0.001 (***). sLOX; soluble LOX-1. EV; empty 9 




3.2.5 LOX-1 Affimers inhibit oxLDL uptake in vitro  2 
 3 
3.2.5.1 Extraction and oxidation of low-density lipoprotein 4 
To facilitate the study of LOX-1 – oxLDL interaction, LDL was isolated from blood 5 
samples taken from healthy human volunteers. LDL particles were purified from 6 
plasma by ultracentrifugation using self-generating gradients of iodixanol 7 
(Graham et al., 1996). This method has several advantages compared with 8 
sodium or potassium bromide gradients; the centrifugation times are shorter and 9 
it negates the need for salt removal (high salt concentrations can modify 10 
lipoprotein structure and therefore require removal) (Chapman et al., 1981; Kelley 11 
and Kruski, 1986). There are multiple documented methods for LDL oxidation, 12 
such as transition metals or incubation with cultured cells. Incubation with copper 13 
sulphate is one of the most reliable and widely used methods for LDL oxidation 14 
(Levitan, Volkov and Subbaiah, 2010) and is the preferred method in the 15 
Ponnambalam lab. The oxidation is halted with the addition of anti-oxidants 16 
ethylene-diaminetetra acetic acid (EDTA) and butylated hydroxytoluene (BHT). 17 
Native and oxidized LDL particles treated with the anti-oxidants EDTA and BHT 18 
were run on 0.5% weight / volume (w/v) agarose gels followed by Sudan black 19 
staining. OxLDL has an increased electrophoretic mobility in comparison to native 20 
LDL as shown in figure 3.8. The increased mobility of oxLDL owes itself to an 21 
increased negative charge due to reactive aldehyde conjugation to lysine 22 
residues during the oxidation process. Oxidation of the LDL particle results in 23 
fragmentation of APO-B100 and aggregation of particles, leading to a relative 24 
heterogeneity of oxLDL particles in the sample, which can be appreciated in 25 
figure 3.8. This method therefore confirms that the LDL particles have undergone 26 











Figure 3.8. Purification and oxidation of low-density lipoprotein particles. 6 
Using iodaxonal gradient centrifugation, low-density lipoprotein (LDL) particles 7 
were extracted from human plasma. LDL was incubated with 5 μM copper 8 
sulphate (CuSO4) for 24 h at 37ºC, leading to oxidation (Oxidised LDL; lanes 2 9 
and 3). A control sample of LDL was incubated with 100 μM EDTA and 20 μM 10 
BHT at room temperature (nLDL; lane 1). Sample were analysed on 0.5% (w/v) 11 




3.2.5.2 Inhibition of oxLDL uptake in LOX-1 expressing HEK-293T cells 1 
LOX-1 Affimers have the potential to competitively bind membrane bound LOX- 2 
1 receptor and inhibit the uptake and internalization of oxLDL. Inhibition of oxLDL 3 
internalization could be of use in the future as a way of attenuating 4 
atherosclerosis by reducing foam cell formation and endothelial dysfunction. To 5 
study the effect of LOX-1 Affimers on oxLDL binding in vitro, oxLDL was labelled 6 
with the fluorescent compound 1,1 dioctadecyl-3,3,3’,3’- 7 
tetramethyllindocarbocyanine perchlorate (DiI). An increasing concentration of 8 
LOX-1 Affimer was incubated with induced HEK-293T cells on ice for 2 h. After 9 
washing, the control (EV) or LOX-FLAG-expressing HEK293T cells were then 10 
incubated with 10µg/ml DiI labelled oxLDL for 15 min on ice. Cells were then fixed 11 
and microscopy analysis (Figure 3.9). As expected, empty vector cells exhibited 12 
minimal oxLDL binding and that in LOX-1 expressing cells, there was a dose- 13 
dependent relationship on oxLDL binding and inhibition by Affimer (Figure 3.9). 14 
A significant reduction in oxLDL binding is observed at 0.1 µg/ml Affimer and a 15 
further reduction is seen at 1 µg/ml Affimer. Inhibitory effects tended to plateau 16 
at concentrations greater than 1 µg/ml, at which point LOX-1 occupancy by 17 





Figure 3.9. LOX-1-specific H1 Affimer inhibits oxLDL uptake in LOX-1- 3 
expressing HEK293T cells. Induced cells are pre-incubated with increasing 4 
concentrations of H1 Affimer, followed by incubation with DiI-labelled oxLDL (red) 5 
for 30 min for either (A) HEK293T-Empty vector, or (B) HEK-293T-LOX-1-FLAG. 6 
Cells were washed, chemically fixed and processed for fluorescence microscopy. 7 





Figure 3.10. Quantification of LOX-1-specific H1 Affimer inhibition of 4 
cellular oxLDL uptake. Quantification of data from Figure 3.9.. There is 5 
significantly decreased oxLDL uptake in LOX-1-expressing HEK293T cells 6 
compared with control empty vector (EV) cells. Error bars denote ±SEM (n=3). 7 
NS; not significant. p<0.01 (**). EV; empty vector. Statistical test: unpaired t-test. 8 
 9 
3.3 Discussion 10 
In this chapter I have described the expression and purification of synthetic 11 
proteins called Affimers and demonstrated their ability to bind the LOX-1 protein 12 
and inhibit oxLDL uptake in vitro. Using Affimers in studies which rely on 13 
fluorescence to quantify an effect e.g. ELISA and cell immunofluorescence, has 14 
clear advantages and drawbacks. Whilst the Affimer scaffold includes a single 15 
cysteine residue to allow binding of either biotin or fluorophore, knowing the 16 
binding efficiency stability are critical for the interpretation of results to draw 17 
confident conclusions. To confirm and quantify Affimer conjugation, the internal 18 
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pixel intensity of the fluorescent band was compared with that of the same band 1 
after staining with coomassie blue. The assumption made is that for 1:1 binding 2 
efficiency one would expect the internal pixel intensity of the two bands to be 3 
equal. A similar method is described by authors measuring protein biotinylation 4 
in vitro and in vivo (Sorenson, Askin and Schaeffer, 2015; Li and Sousa, 2012). 5 
While this method has clear advantages (quick, accessible), it requires validation. 6 
The LOX-1 SR is encoded by the ORL-1 gene found on chromosome 12p12-p13 7 
in humans (AOYAMA et al., 1999). Human LOX-1 is a 273 amino acid protein 8 
with 4 domains; a short N-terminal cytoplasmic, a transmembrane, a connecting 9 
neck, and a lectin-like domain at the C terminus which binds oxLDL (Zani et al., 10 
2015). The conservation of the amino acid sequence of the lectin-like domain is 11 
essential for oxLDL binding, where 6 cys repeats are thought to be most critical. 12 
This has been demonstrated by Chen et al. where truncation and point mutations 13 
in the lectin-like domain led to abrogation of oxLDL binding (CHEN et al., 2001; 14 
Chen et al., 2001a). OxLDL binding in scavenger receptors SR-A and CD36 are 15 
thought to be largely dependent on the expression of electrostatic 16 
residues(Andersson and Freeman, 1998; Pearce et al., 1998). Chen et al. 17 
hypothesize a similar dependence on electrostatic interaction between positively 18 
charged residues in LOX-1 lectin-like domain and negatively charged oxLDL, in 19 
particular involving the large loop between the 3rd and 4th cys of the lectin-like 20 
domain, where mutations in this region led to the abolition of oxLDL binding (Chen 21 
et al., 2001a). The Affimer proteins were isolated by phage display against the C- 22 
type lectin-like domain region of LOX-1 and should have the ability to bind this 23 
region, however the binding properties should not be assumed to be identical to 24 
that of oxLDL. The variable regions of the 5 LOX-1 Affimer isoforms may bind the 25 
lectin-like domain at different points and with varying affinities. Variations in the 26 
amino acid sequence of the Affimer binding region are likely to affect affinity, as 27 
shown similarly in the optimization of monoclonal antibodies (Kaneko and Niwa, 28 
2011). Affinity assays against human LOX-1 demonstrate some variation, 29 
however these were not statistically significant. Comparative affinity assays 30 
against the mouse LOX-1 protein found a significant variation between isoforms. 31 
The mouse LOX-1 protein is similar to the human protein in that it contains the 32 
same 4 regions, but in contrast contains triple repeats of the extracellular neck 33 
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region, increasing its size to 363 amino acids (Hoshikawa et al., 1998) (figure 1 
1.5). Mouse LOX-1 has been shown to bind oxLDL with high affinity similar to the 2 
human receptor, however the sequence % identity of the lectin-like domain in 3 
mouse LOX-1 compared with human LOX-1 is 59% with % similarity of the protein 4 
being relatively conserved at 86%. Variations in the amino acid sequence at the 5 
lectin-like domain are likely to influence Affimer binding affinities between 6 
isoforms as shown by the affinity assays against mouse LOX-1. 7 
Affimers had the ability to bind membrane-bound LOX-1 and inhibit oxLDL 8 
binding in vitro. The concentrations required to show binding were higher than 9 
those required to begin inhibiting oxLDL binding. One potential explanation for 10 
this is that cys-fluorophore disulphide bonds are gradually reduced in storage. 11 
Unbound Affimers would have the potential to polymerize with other Affimers via 12 
the cys residues or with fluorophores already bound to other Affimer molecules. 13 
This would have a negative effect on signal strength as the percentage of 14 
conjugated Affimer in solution would be reduced. Alternatively, Affimer binding 15 
may be leading to downregulation of LOX-1 expression as observed in similar 16 
studies using anti-LOX-1 antibodies (Abdul-Zani (2017) PhD thesis). 17 
Downregulation of LOX-1 expression at lower concentrations of LOX-1 Affimer 18 
would lead to an enhanced effect on oxLDL binding and internalization compared 19 
with competitive inhibition alone. An important limitation to highlight is the use of 20 
a non-vascular cell type in the cell-based experiments. The advantage of using 21 
the tetracycline-inducible HEK293T cell line is that in the absence of tetracycline, 22 
they do not express detectable levels of LOX-1 protein. The same tetracycline- 23 
inducible expression system was introduced in primary endothelial cell lines such 24 
as porcine aortic endothelial cells by previous researchers in the Ponnambalam 25 
group. The endogenous expression of LOX-1 in these cell lines in the absence 26 
of tetracycline was significant and therefore the lack of a reliable negative control 27 
for the study of LOX-1-oxLDL binding led to the development of the LOX-1 28 
expressing HEK293T cell line. This system is preferable for the study of LOX-1 29 
binding for the above reasons, however it is not physiological and any future 30 
studies on the downstream effects of LOX-1-oxLDL binding should take this in to 31 
consideration and employ the use of a vascular cell line.  32 
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In summary, LOX-1 Affimers can be reliably expressed in E. coli and purified 1 
using immobilised metal affinity chromatography. LOX-1 Affimers exhibit affinity 2 
for human and mouse LOX-1. There is variation in affinity for mouse LOX-1 3 
among Affimer isoforms, which is likely attributable to sequence variations in the 4 
lectin-like domain in human and mouse LOX-1, and at each Affimer variable 5 
regions. The H1 Affimer binds both human and mouse LOX-1 with high affinity 6 
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CHAPTER 4 1 
LOX-1 GENOTYPE INFLUENCE ON DISEASE STATES 2 
 3 
4.1 Introduction 4 
Atherosclerosis is a complex systemic disease process resulting from multiple 5 
environmental and genetic factors. The complexity of atherosclerosis research 6 
has given rise to the use of different animal models which aim to mimic human 7 
disease, of which the mouse model is the most frequently used (Mukhopadhyay, 8 
2013). Mouse models come with several advantages, the most important of which 9 
is the similarity between the mouse and human genome (95% concordance in 10 
protein-coding regions). A recent systematic review of genome-wide association 11 
studies (GWASs) in coronary artery disease found a striking concordance in risk 12 
factors for atherosclerosis and a significant overlap in the 827 genes identified by 13 
GWASs (von Scheidt et al., 2017). Mouse models offer many practical 14 
advantages over larger animals: 15 
• The costs of breeding, feeding and maintenance are significantly lower and 16 
their growth rate and generation time is rapid.  17 
• Given their small size, the use of pharmaceuticals as part of an experiment 18 
becomes more affordable as lower volumes are required.  19 
• There is a wide availability of inbred transgenic strains and genetic knockout 20 
techniques are easily employed to study the effects of specific genetic loci 21 
(Lee et al., 2017). 22 
 23 
One disadvantage of mouse models in the study of atherosclerosis is their relative 24 
resistance to the development of atherosclerosis compared with humans 25 
(Breslow, 1996). To induce atherosclerosis in wild-type mice, non-physiological 26 
levels of cholesterol must be added to their diet; specifically 10-20 times that of a 27 
typical Western diet (WD) (Breslow, 1996). In response to this problem, 28 
transgenic APO-E (apolipoprotein-E) null mice were created using gene knockout 29 
technology in the early 1990’s (Plump et al., 1992). APO-E is surface constituent 30 
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of lipoprotein particles and a ligand for lipoprotein recognition and clearance by 1 
lipoprotein receptors. Deficiency of APO-E hence leads to the spontaneous 2 
development of atherosclerosis, which can be further enhanced by the 3 
introduction of a high cholesterol WD (Davignon, 2005). Genetic engineering of 4 
APO-E deficient mice to produce double-knockout strains is frequently used to 5 
study the role of different proteins in atherogenesis, particularly in the search for 6 
potential therapeutic target proteins.  7 
Investigators have studied the relationship between scavenger receptor (SR) 8 
expression and atherogenesis using such double knockout mouse models with 9 
some success (Babaev et al., 2000; Manning-Tobin et al., 2009; Mehta Jawahar 10 
et al., 2007; Aslanian and Charo, 2006; Soro-Paavonen et al., 2008). Much of the 11 
literature reports an anti-atherogenic in SR deletion, however there are a small 12 
number of conflicting articles, particularly those studying the deletion of multiple 13 
SR subtypes in a single subject (Mäkinen et al., 2010; Manning-Tobin et al., 2009; 14 
Kuchibhotla et al., 2008). The reciprocal upregulation of one SR when another is 15 
downregulated is of particular concern, as reported by Manning-Tobin et al 16 
(Manning-Tobin et al., 2009). Such effects represent potential negative 17 
implications for the application of SR targeting in the treatment of atherosclerotic 18 
disease.  19 
Synthetic binding proteins (Affimers) specific to human LOX-1 inhibit oxLDL 20 
uptake in-vitro, as described in Chapter 3. Whist this result is promising, it does 21 
not go as far as proving an anti-atherogenic capability of LOX-1 Affimers as the 22 
LOX-1 mediated uptake of oxLDL by immune cells represents only a single step 23 
in atherogenesis. Furthermore, these results must be interpreted in the context 24 
of highly controlled in-vitro experimental conditions.  25 
To study the effects of LOX-1 Affimers in atherogenesis, a mouse model of 26 
atherosclerosis offers a more comprehensive assessment. ELISA was used to 27 
identify cross-reactive LOX-1 Affimers between human and mouse LOX-1. The 28 
H1 LOX-1 Affimer exhibited equal affinity to both human and mouse LOX-1 29 
extracellular domains, allowing us to move forward with an in-vivo study using 30 
LOX-1 Affimer as a potential therapeutic agent in atherosclerosis. One study has 31 
reported the attenuation of atherosclerosis with LOX-1 deletion in LDLR deficient 32 
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mice and several others have found similar effects using anti-LOX-1 antibody 1 
administration (Mehta Jawahar et al., 2007; Dominguez et al., 2008; Li et al., 2 
2002b).  3 
Invasive interventions for atherosclerotic cardiovascular disease e.g. angioplasty 4 
/ stenting and arterial surgery are key components of current best medical 5 
practice. Despite the development of more advanced techniques and improved 6 
outcomes in some areas, the problem of neointimal hyperplasia (NIH) persists to 7 
negatively impact on durability. NIH is an inflammatory process defined by 8 
thickening of the intimal layer due to the proliferation of VSMCs) and the 9 
production of extra-cellular matrix (Kijani et al., 2017). Intimal thickening leads to 10 
luminal narrowing, restenosis and potentially arterial / graft occlusion. Whist there 11 
is a degree of overlap between NIH and atherosclerosis, the two processes are 12 
pathologically separate entities (Subbotin, 2007). The role of SR expression in 13 
NIH have been investigated, with reports of potential involvement of LOX-1 and 14 
CD36 (Hinagata et al., 2006; Yue et al., 2019). The work in this chapter is to 15 
evaluate the effects of LOX-1 Affimer inhibition and LOX-1 deletion on lipid and 16 
glucose metabolism, atherogenesis and NIH in APO-E null mice. 17 
 18 
4.2 Study design and mouse genotyping 19 
The study was designed to study the effects of both LOX-1 Affimer administration 20 
and LOX-1 deletion on a variety of processes linked to lipid metabolism and 21 
atherosclerosis. A proportion of the study was intended to reproduce and add to 22 
work completed by the Ponnambalam laboratory on the LOX-1 project. 23 
Three transgenic lines were used for this study: 24 
• APO-E null 25 
• APO-E/LOX-1 null 26 
• LOX-1 null 27 
 28 
The central aim was to compare outcomes between 3 groups (Figure 4.1): APO- 29 
E null (control) (n=4) vs. APO-E-null treated with LOX-1 Affimer (n=4) vs. APO- 30 
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E/LOX-1 null mice (n=5). The number of mice in each group were decided based 1 
on available resources, particularly the availability of osmotic pumps. For this 2 
reason, a power calculation was not performed and therefore we accept that this 3 
pilot study is underpowered. Due to the small numbers in each group and the 4 
limited number of researchers involved in the project, the analysis of specimens 5 
was not blinded or randomized as recommended by the “ARRIVE guidelines 2.0” 6 
(Percie du Sert et al., 2020).  7 
Both LOX-1 null and wild type mice were used for additional comparison, 8 
particularly to demonstrate specimens free of disease. Maintaining accurate 9 
genotyping of transgenic lines is vital to ensure reliability of results and 10 
conclusions. Preserving a homozygous APO-E null genotype is essential, as 11 
heterozygous APO-E null mice will not spontaneously exhibit a typical APO-E null 12 
lipid phenotype. Only small amounts of circulating APO-E is necessary to 13 
dampen the expected phenotype, leading to protection from diet-induced 14 
atherosclerosis (Davignon, 2005). 15 
The genotype of breeding pairs (1 female, 2 males) were regularly assessed by 16 
subjecting ear notch tissues to PCR and DNA analysis. The APO-E null C57Bl/6 17 
mouse line showed the presence of a 245 bp DNA fragment, consistent with loss 18 
of a functional APO-E allele. C57Bl/6 wild type DNA was used as a control and 19 
showed the presence of a 155 bp DNA fragment, indicating the presence of a 20 
functional APO-E allele or locus (Figure 4.2A). LOX-1 null mice displayed loss of 21 
405 bp sequence within exon 7 of the mouse LOX-1 (OLR1) gene compared with 22 
the presence of a band at 405 bp in control wild-type mice (Figure 4.2B) 23 








Figure 4.1. Schematic of mouse studies. 3 mouse groups for comparison were 7 
APO-E null, APO-E null treated with 8 weeks of LOX-1-specific Affimer via 8 
subcutaneous osmotic pump, and APO-E/LOX-1 null. Separate experiments in 9 




Figure 4.2. Genotyping transgenic mouse lines. APO-E-null, LOX-1-null, and 3 
wild-type mice were genotyped for LOX-1 and APO-E alleles using polymerase 4 
chain reaction (PCR). (A) With DNA primers specific for APO-E locus, a smaller 5 
DNA band (155 bp) indicates presence of the gene whilst a larger DNA band (245 6 
bp) indicates absence of a functional APO-E allele. (B) The presence of a DNA 7 
band (405 bp) with LOX-1 primers indicates a functional LOX-1 (OLR1) allele 8 
whilst its loss signifies a homozygous knockout strain.  9 
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4.3 Results 1 
4.3.1 Influence of LOX-1 on body mass 2 
The association between LOX-1 function and obesity is only partly understood. 3 
Animal and human studies have found increased levels of soluble urinary and 4 
serum LOX-1 in obese subjects (Kelly et al., 2008; Brinkley et al., 2008). An in- 5 
vitro study of oxLDL uptake in adipocytes found that LOX-1 expression in 6 
adipocytes was associated with significant increase in fatty acid uptake (Chui et 7 
al., 2005). The results from these studies suggest a link between increased LOX- 8 
1 expression and obesity, however results from transgenic mouse models of 9 
LOX-1 knockout have reported no significant differences in diet-induced weight 10 
gain or mesenteric fat deposition in association with LOX-1 knockout (Takanabe- 11 
Mori et al., 2010; Mehta Jawahar et al., 2007). 12 
To investigate the effects of LOX-1 modulation in APO-E null mice, transgenic 13 
mice were inspected and weighed on a weekly basis from the beginning of their 14 
12 week WD regimen (8 weeks old) until completion at 12 weeks of WD (20 15 
weeks old). In addition, mice undergoing procedures were weighed before 16 
starting.  17 
A line graph of the mean weight of mice at 0, 6 and 12 weeks of WD (Figure 4.3A) 18 
shows a steeper increase in weight in the APO-E null mice within the first 6 weeks 19 
compared with APO-E/LOX-1 null and Affimer-treated APO-E null mice. The 20 
mean total weight gain was compared (Figure 4.3B) and showed that both APO- 21 
E/LOX-1 null (p=0.0121) and Affimer-treated APO-E null mice (p=0.0210) gained 22 




Figure 4.3 Weight of transgenic mice upon Western diet treatment and LOX- 3 
1-specific Affimer treatment. (A) Graph showing mouse weight gain over 12 4 
weeks of Western diet. (B) Comparison of total weight gain. At 12 weeks, APO- 5 
E/LOX-1 null and APO-E null Affimer treated mice had gained significantly less 6 
weight compared with APO-E null mice alone. Error bars denote ±SEM (n=4). 7 
p<0.05 (*). Statistical test: One-way ANOVA. 8 
 9 
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4.3.2 Effects of LOX-1 on insulin resistance 1 
There are multiple reports of an association between glucose homeostasis and 2 
LOX-1 expression. Investigators have shown that LOX-1 expression and 3 
monocyte adhesion increases when endothelial cells are exposed to increasing 4 
concentrations of glucose in-vitro (Li, Sawamura and Renier, 2003). In diabetic 5 
rats, vascular LOX-1 expression is increased compared with non-diabetic 6 
controls (Chen et al., 2001c). Studies investigating SR expression and insulin 7 
resistance in adipocytes have shown that LOX-1 expression leads to increased 8 
insulin resistance in adipocytes, suggesting a possible mechanistic association 9 
with diabetes mellitus and atherosclerosis (Rasouli et al., 2009; Chui et al., 2005). 10 
To investigate the possible association between LOX-1 expression and insulin 11 
resistance in mice, subjects within the 3 study arms underwent a glucose 12 
tolerance test (GTT) and insulin tolerance test (ITT) at 0 and 12 weeks of WD. 13 
There was no significant difference in fasting blood glucose levels between the 3 14 
groups at 0 and 12 weeks after WD (Figure 4.4). The fasting blood glucose levels 15 
did not change significantly between 0 to 12 weeks in any group under all 16 
conditions examined.  17 
GTT and ITT results were similar for all 3 groups at 0 weeks WD (Figure 4.5A, 18 
4.6A). After 12 weeks of WD treatment, the GTT and ITT curves in the APO-E 19 
null mice showed differences, whilst curves plotted for APO-E/LOX-1 null and 20 
Affimer-treated APO-E null mice remained unchanged (Figure 4.5B, C; Figure 21 
4.6B, C). Area-under-curve (AUC) analysis demonstrated that APO-E null mice 22 
were significantly more insulin resistant at ITT compared with APO-E/LOX-1 null 23 
(p=0.0001) and Affimer-treated APO-E null mice (p=0.0273) after 12 weeks of 24 
WD. APO-E null mice were significantly more glucose intolerant compared with 25 
Affimer-treated APO-E null mice (p=0.0029) after 12 weeks of WD. The APO-E 26 
null mice suggested an increase in glucose intolerance compared to the APO- 27 
E/LOX-1 null mice, but this was not statistically significant. In APO-E null mice, 28 
blood glucose levels increased in response to glucose administration (GTT) and 29 
decreased less in response to insulin administration (ITT), indicating increased 30 
insulin resistance associated with WD treatment. Interestingly, this change was 31 
not observed in the APO-E/LOX-1 null or Affimer-treated APO-E null mice, 32 
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suggesting the possibility of a protective effect associated with LOX-1 deletion or 1 






Figure 4.4. Fasting glucose effects in transgenic mice after Western diet. 8 
Mice were fasted for 6 h prior to serum glucose measurement. There were no 9 
significant differences between lines pre- and post-Western diet. Fasting serum 10 
glucose in each transgenic line was compared pre- and post-Western diet and 11 
there were no significant differences. Error bars denote ±SEM (n=4). NS; not 12 





Figure 4.5. Glucose tolerance test (GTT) of transgenic mice after Western 3 
diet. (A) pre-Western diet, showing little or no difference. (B) GTT post-Western 4 
diet shows that the APO-E null subjected to LOX-1-specific Affimer treatment 5 
group had a significantly improved glucose tolerance compared with untreated 6 
APO-E mice. (C) GTT data analysis for each separate group. Error bars denote 7 
±SEM (n=4). NS; not significant. p<0.01 (**). GTT; glucose tolerance test. AUC; 8 
area under the curve. WD; Western diet. Statistical test: (A), (B) One-way 9 




Figure 4.6. Insulin tolerance test (ITT) of transgenic mice after Western diet. 3 
(A) ITT analysis pre-Western diet, showing there is no significant difference 4 
between groups. (B) ITT analysis post-Western diet, The APO-E/LOX-1 null and 5 
APO-E + affimer groups exhibit increased insulin sensitivity compared with APO- 6 
E null mice. (C) ITT comparison in each of group pre- and post-Western diet. 7 
Error bars denote ±SEM (n=4). NS; not significant. p<0.05 (*). p<0.0001 (****). 8 
ITT; insulin tolerance test. AUC; area under the curve. WD; western diet. 9 
Statistical test: (A), (B) One-way ANOVA, (C) Paired t-test. 10 
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4.3.3 Effects of LOX-1 on hepatic steatosis 1 
Non-alcoholic steatohepatitis (NASH) is the most common cause of chronic liver 2 
disease worldwide and its prevalence worldwide is increasing (Rafiq and 3 
Younossi, 2009). NASH is widely accepted to be a hepatic manifestation of 4 
metabolic syndrome. It has been linked to mechanisms involving lipid-mediated 5 
macrophage activation, a feature it holds in common with atherogenesis and the 6 
development of cardiovascular disease (Ho et al., 2019). The potential role of 7 
LOX-1 in NASH has been investigated in both experimental animal models and 8 
in patients. A mouse model of NASH found that LOX-1 expression was required 9 
for hepatic fibrogenesis while cohort studies of patients with known NASH 10 
demonstrate that hepatic LOX-1 expression and soluble serum LOX-1 levels are 11 
increased in the presence of NASH (Ho et al., 2019; Musso et al., 2011; Ozturk 12 
et al., 2015). The opportunity was taken as part of our study to investigate the 13 
role of LOX-1 in the development of hepatic steatosis.  14 
After 12 weeks of WD, all major abdominal organs in mouse groups subjected to 15 
different experimental regimes were harvested along with the aorta, carotid and 16 
femoral arteries as described in Materials and Methods. During each tissue 17 
harvest, the most anterior segment of the liver was taken for processing followed 18 
by paraffin embedding. 5 µm thick liver sections were processed for histological 19 
analysis and stained with haematoxylin and eosin (Figure 4.7). The total surface 20 
area of steatosis was measured and used to calculate the % hepatic steatosis 21 
using previously published methods (Matsuzawa et al., 2007; Ho et al., 2019).  22 
All 5 groups exhibited varying degrees of hepatic steatosis (Figure 4.7A). The 23 
degree of fat infiltration was quite marked in all groups except for wild-type 24 
genotype (Figure 4.7A). Increased % of coverage of tissue exhibiting the hepatic 25 
steatosis phenotype was observed in APO-E null, APO-E/LOX-1 null and Affimer- 26 
treated APO-E null mice compared to wild-type mice (Figure 4.7A), however 27 
these were not statistically significant (Figure 4.7B). Unexpectedly, LOX-1 null 28 
mice exhibited large areas of fat infiltration and we found the % fat infiltration was 29 
significantly increased compared with wild type mice (p=0.0027) (Figure 4.7B). 30 
These findings suggest that the LOX-1 null genotype influences hepatic fat 31 




Figure 4.7. Effect of LOX-1 on hepatic fat deposition. (A) Sections of liver from 3 
mice subjected to Western diet, processed for histology and stained with 4 
haematoxylin and eosin. The fat cells are discrete rounded areas containing no 5 
stain. (B) Compared with wild-type mice, LOX-1 null mice showed a significant 6 
increase in fat deposition after Western diet. Magnification 20X , scale bar = 100 7 
µm. Error bars denote ±SEM. All groups n=4. NS; not significant. p<0.01 (**). WT; 8 
wild type. Statistical test: One-way ANOVA. 9 
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4.3.4 LOX-1 influence on atherogenesis 1 
To achieve a comprehensive assessment of atherogenesis, regions most prone 2 
to large vessel disease were harvested for analysis. The analyzed regions 3 
included whole aorta, femoral artery and the common carotid bifurcation. 4 
Measurement of % plaque area in whole aortic specimens is an established 5 
method for assessing atherosclerotic burden in mouse models of atherosclerosis 6 
(Lee et al., 2017; Emini Veseli et al., 2017). Probably the most clinically relevant 7 
sites of large vessel atherosclerosis in humans are at the femoral and carotid 8 
bifurcations. Disease at these locations can lead to peripheral arterial and 9 
cerebrovascular disease, respectively. Upregulation of LOX-1 in a mouse model 10 
of atherosclerosis is associated with greater carotid plaque burden (White, Sala- 11 
Newby and Newby, 2011). Sites of arterial branching or bifurcation are most 12 
susceptible to atherosclerosis. Haemodynamic shear stress in these areas has 13 
been shown to modulate endothelial expression of a variety of molecules involved 14 
in atherogenesis, including LOX-1 (Murase et al., 1998). 15 
Whole aortic mouse specimens were fixed and stained with oil red O as described 16 
in Materials and Methods. There was a reduction in % plaque area in all groups 17 
compared to the APO-E null group (Figure 4.8A, 8B). The >60% reduction in 18 
plaque area was statistically significant in the APO-E/LOX-1 null mice (p=0.0075) 19 
(Figure 4.8B). The reduction in plaque area in the Affimer-treated group was not 20 
statistically significant (Figure 4.8B). For comparison, whole aortic specimens 21 
from LOX-1 null mice fed 12 weeks of WD are included in the analysis (Figure 22 
4.8A).  23 
Carotid bifurcation atherosclerosis is important clinically as disease at this 24 
location can give rise to cerebrovascular accidents in humans. Bilateral carotid 25 
arteries were harvested and stained with. Miller / Van Gieson stain and analysed 26 
for % plaque area at or immediately distal to the common carotid bifurcation 27 
(Figure 4.9). All groups exhibited a degree of bifurcation disease except for the 28 
LOX-1 null genotype, which was generally low in plaque staining (Figure 4.9A). 29 
Carotid bifurcation atherosclerotic plaque incidence was reduced non- 30 
significantly in APO-E/LOX-1 null and statistically significantly in Affimer-treated 31 
APO-E null mice (p=0.0328) compared with APO-E controls (Figure 4.9B). LOX- 32 
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1 null mice exhibited significantly less carotid atherosclerosis compared with 1 
APO-E null controls (p= 0.009) (Figure 4.9B). 2 
Atherosclerotic disease at the level of the femoral artery is also important clinically 3 
as disease at this level is a common cause of peripheral artery disease, which 4 
can lead to limb and life threatening complications in humans. Bilateral femoral 5 
arteries were harvested and specimens were stained and analysed (Figure 4.10). 6 
Mice which had undergone unilateral femoral artery wire injury at week 8 of 7 
Western diet had the contralateral femoral artery analysed for plaque incidence 8 
and distribution (Figure 4.10). All groups exhibited a degree of femoral artery 9 
disease except for the LOX-1 genotype, which was generally disease free (Figure 10 
4.10A). There were significant reductions in atherosclerosis at this level in APO- 11 
E/LOX-1 null (p=0.0296) and LOX-1 null mice (p=0.0153) (Figure 4.10B). There 12 
was a reduction in atherosclerosis in the Affimer-treated APO-E null mice, but 13 
this was not statistically significant (Figure 4.10B). 14 
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 1 
Figure 4.8. LOX-1 allele influences atherosclerotic plaque incidence in APO- 2 
E null mice. The total atherosclerotic load in harvested aortae stained with oil 3 
red O (A) . Whilst the LOX-1 null genotype significantly modulated atherosclerotic 4 
load, reductions observed in the LOX-1 Affimer treated group was non-significant 5 
(B). Scale bar = 10mm. Error bars denote ±SEM. APO-E null n=4, APO-E null + 6 
affimer n=4, APO-E/LOX-1 null n=6, LOX-1 null n=4. NS; not significant. p<0.01 7 
(**). Statistical test: One-way ANOVA. 8 
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 1 
Figure 4.9. LOX-1-specifc Affimer effect on carotid atherosclerosis. (A) The 2 
carotid arteries of Western diet fed transgenic mice were processed for histology 3 
and Miller elastin staining and analysed immediately distal to the common carotid 4 
bifurcation. (B) Quantification of % plaque in carotid areas under the different 5 
treatment conditions. Magnification 10X, scale bar = 100 µm. Error bars denote 6 
±SEM. APO-E null n=6, APO-E null + affimer n=6, APO-E/LOX-1 null n=4, LOX- 7 
1 null n=3.  (n=4). NS; not significant. p<0.05 (*), p<0.01 (**). Statistical test: One- 8 
way ANOVA. 9 
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 1 
Figure 4.10 LOX-1-specific Affimer effects on femoral atherosclerosis. (A) 2 
The femoral arteries of Western diet fed transgenic mice were processed for 3 
histology and Miller elastin staining and analysed at and immediately proximal to 4 
the femoral bifurcation. B) Quantification of % plaque in carotid areas under the 5 
different treatment conditions. Magnification 10X, scale bar = 100 µm. Error bars 6 
denote ±SEM. APO-E null n=6, APO-E null + affimer n=3, APO-E/LOX-1 null n=4, 7 
LOX-1 null n=3. NS; not significant. p<0.05 (*), p<0.01 (**). Statistical test: One- 8 
way ANOVA. 9 
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4.3.5 The influence of LOX-1 on neointimal hyperplasia in the femoral artery 1 
NIH is a phenomenon which primarily affects arteries and vein grafts which have 2 
been subject to either open surgery in the form of bypass grafting and / or 3 
radiological intervention in the form of angioplasty and/or stenting. Post- 4 
procedural NIH can give rise to graft failure, arterial restenosis, and/or occlusion, 5 
leading to potential limb or life threatening consequences for patients. Animal 6 
studies investigating the role of LOX-1 in NIH have found that LOX-1 expression 7 
in VSMC is upregulated post-vascular injury; the proliferation of VSMCs 8 
increased when exposed to oxLDL, suggesting that LOX-1 may mediate an 9 
oxLDL-induced VSMC proliferation in NIH post-vascular injury (Eto et al., 2006). 10 
Hingata et al. demonstrated that LOX-1 inhibition using and anti-LOX-1 antibody 11 
reduced NIH, oxidative stress and leucocyte infiltration in a rat model of carotid 12 
artery injury (Hinagata et al., 2006). 13 
Two mouse models for NIH are well described in the literature: carotid artery 14 
ligation with cessation of blood flow and mechanically-induced denudation of 15 
endothelium in the carotid or the femoral arteries (Hui, 2008). To denude the 16 
endothelium, normally either an angioplasty guide-wire or an angioplasty balloon 17 
is used to injure the vessel. We have experience of using wire-guided damage to 18 
the femoral artery to assess effects of genotype and experimental conditions 19 
(Kahn et al., 2011; Cubbon et al., 2014). WD-fed mice in the APO-E null, APO- 20 
E/LOX-1 null and Affimer-treated APO-E null mice underwent unilateral femoral 21 
artery wire injury after 8 weeks of WD. This allowed 4 weeks for NIH lesions to 22 
form by the date of harvest. Femoral artery specimens were stained with Miller / 23 
Van Gieson technique and analysed for % plaque coverage of the arterial bed. 24 
Identification of the outer and inner elastic lamina of the medial layer proved 25 
difficult in most specimens due to hyperplasia and distortion in the medial layer. 26 
This was likely a result of injury to the medial layer in addition to the intimal layer 27 
during wire injury.  28 
At microtomy, multiple sections of femoral artery from distal to proximal were 29 
mounted and viewed (Figure 4.11). For each mouse, the specimen showing the 30 
highest degree of NIH was analysed. All 3 groups formed femoral artery NIH 31 
lesions after wire injury (Figure 4.11A). There was a significant reduction in NIH 32 
in the femoral arteries of APO-E/LOX-1 null mice compared with APO-E null mice 33 
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(p=0.0368) (Figure 4.11B). Affimer-treated APO-E null mice exhibited a non- 1 
significant reduction in NIH compared with APO-E null mice (Figure 4.11B).  2 
4.3.6 LOX-1 affimer biodistribution studies 3 
To evaluate the delivery of Affimer protein using continuous subcutaneous 4 
infiltration via osmotic pumps, pumps containing 1 mg/ml biotinylated LOX-1 5 
Affimer were implanted in to 4 LOX-1 null mice. At 1, 2, 3 and 4 weeks’ post- 6 
implantation, a mouse was culled and serum, urine and major organs were 7 
harvested for analysis. Serum and urine samples were serially diluted and 8 
analysed by SDS-PAGE electrophoresis, followed by western blotting using a 9 
streptavidin-HRP detection system. Major organs were snap frozen in liquid 10 
nitrogen immediately after harvesting. Frozen organ samples were ground using 11 
a pestle and mortar and lysed using 1 X Radio-immunoprecipitation assay (RIPA) 12 
buffer. The lysate was extracted after centrifugation and analysed in the manner 13 
described above. 14 
In serum, urine and organ lysates, biotinylated LOX-1 Affimer was not detectable 15 
in the western blots. Bands at 11-14 kDa on electrophoresis were obscured by 16 




Figure 4.11 LOX-1 knockout reduces neointimal hyperplasia in APO-E null 2 
mice. (A) Unilateral femoral artery wire injury was carried out after 8 weeks of 3 
Western diet and the degree of neointimal hyperplasia (NIH) after a further 4 4 
weeks was assessed using histology as previously described. (B) Quantification 5 
of morphological effects staining in femoral artery areas under the different 6 
treatment conditions. Magnification 10X, scale bar = 100 µm. Error bars denote 7 
±SEM. APO-E null n=5, APO-E null + affimer n=7, APO-E/LOX-1 null n=5. NS; 8 








Figure 4.12. Detection of biotinylated LOX-1 affimers in mouse serum. (A) 6 
Coomassie stained protein gel electrophoresis of harvested serum from mice 7 
treated with biotinylated LOX-1 affimer, compared with positive control (LOX-1 8 
affimer in solution) and negative control (serum from an untreated mouse). (B) 9 
Western blotting with streptavidin-HRP detection system failed to detect the 10 
presence of a band at 11-14 kDa.  11 
 12 
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4.4 Discussion 1 
The main aim of these studies using animal models was to evaluate the effects 2 
of the LOX-1 inhibition using Affimers in the development of atherosclerosis and 3 
NIH. Furthermore, the contribution of LOX-1 to other disease states including 4 
insulin resistance and hepatic steatosis was explored in this context.  In summary, 5 
we found that LOX-1 ablation was associated with reduced insulin resistance, 6 
reduced atherosclerotic burden and protection against NIH. It was unexpected 7 
that the LOX-1 null mice would have a significantly increased accumulation of 8 
lipid within the liver, given the apparent association between increased LOX-1 9 
expression and NASH in humans, and the observed resistance to atherogenesis 10 
seen in the LOX-1 null mice. 11 
The first transgenic study of LOX-1 knockout was published by Mehta, Sawamura 12 
and colleagues in 2007 (Mehta Jawahar et al., 2007). LDLR null and LDLR/LOX- 13 
1 null mice were fed a high cholesterol diet for 18 weeks and aortic plaque 14 
coverage was compared between colonies. The authors reported amelioration of 15 
atherogenesis with LOX-1 ablation in the LDLR null mice. From our study of LOX- 16 
1 ablation in APO-E null mice, findings from the analysis of aortic atherosclerosis 17 
reproduce previous work, adding strength to the argument that LOX-1 plays an 18 
important role in oxLDL mediated atherogenesis and that it is an attractive 19 
potential therapeutic target. Aortic atherosclerosis is useful as a surrogate 20 
measure of global atherosclerotic burden in experimental animal models, 21 
however this method is limited by the lack of information on plaque thickness and 22 
cellular composition.  23 
Aortic atherosclerosis in human subjects is relevant for its association with clinical 24 
outcomes. Multiple studies of the relationship between aortic plaque and the 25 
incidence of embolic stroke have reported an association between plaque 26 
severity or thickness and the risk of embolic stroke (Kronzon and Tunick Paul, 27 
2006). These studies also found that plaque severity was associated with 28 
increased atherosclerosis at the carotid bifurcation and the prevalence of other 29 
risk factors such as advanced age, hypertension, hypercholesterolaemia and 30 
smoking status, suggesting that aortic plaque is a marker for global 31 
atherosclerotic burden and cardiovascular risk, rather than playing a direct role 32 
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in pathogenesis. Our study was designed to include an analysis of carotid and 1 
femoral artery bifurcation atherosclerosis, as disease at these anatomical 2 
locations do give rise to clinical manifestations in humans. LOX-1 knockout in 3 
APO-E null mice did result in a reduction in atherosclerosis in the carotid and 4 
femoral arteries, however only significantly in the femoral arteries. Endothelial 5 
LOX-1 expression is modulated by alterations in shear stress, implicating it as a 6 
likely contributor in the development of lesions at arterial bifurcations and branch 7 
ostia (Murase et al., 1998). Our findings support this theory, suggesting that LOX- 8 
1 targeting has a potential role in reducing atherogenesis at clinically important 9 
regions of altered shear stress and turbulent flow. The differences in the 10 
topography and causation of atherosclerosis between mice and humans puts 11 
limitations on the interpretation of our results. In a mouse model, experimental 12 
conditions are tightly controlled and while variables and their relationship to LOX- 13 
1 can be investigated individually, any drawn conclusion is limited when applied 14 
to the average co-morbid arteriopathic patient. The anatomical distribution of 15 
atherosclerosis in atherosclerosis-prone transgenic mice (APO-E null / LDLR 16 
null) differs from humans: they are particularly prone to disease at the aortic 17 
sinus, the lesser curvature of the aortic arch and branch points of the 18 
brachiocephalic, subclavian and left carotid arteries (Emini Veseli et al., 2017). In 19 
contrast, the distribution of disease in humans is highly variable and strongly 20 
depends on a wide variety of risk factors including smoking status, diabetes 21 
mellitus, hypertension and lipid profile to name only a few (VanderLaan Paul, 22 
Reardon Catherine and Getz Godfrey, 2004; Yasaka, Yamaguchi and Shichiri, 23 
1993).  24 
Mice are well understood to be resistant to atherosclerosis, hence the need for 25 
gene knockout models to accelerate diet-induced atherogenesis for research 26 
purposes (VanderLaan Paul, Reardon Catherine and Getz Godfrey, 2004). The 27 
pro-atherogenic genetic knockout component of the model (in this case, APO-E 28 
knockout) must also be taken in to account when considering the transferability 29 
of results to human patients. APO-E is a 34 kDa glycoprotein synthesized mainly 30 
in the liver and brain (Curtiss and Boisvert, 2000). It is a structural component of 31 
all lipoprotein particles except low-density lipoprotein particles and serves as a 32 
ligand for cell surface lipoprotein receptors whose function is to clear 33 
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chylomicrons and VLDL particle remnants (Curtiss and Boisvert, 2000). When 1 
fed a high cholesterol diet, APO-E null mice exhibit a lipid phenotype which is 2 
atypical of the human profile, with disproportionately raised VLDL levels and a 3 
total plasma cholesterol level 4 times that of chow-fed wild type mice (Plump et 4 
al., 1992; Nakashima et al., 1994; Emini Veseli et al., 2017). LDL levels are raised 5 
in APO-E null mice albeit to a lesser extent than VLDL, therefore the role of LOX- 6 
1/oxLDL mediated atherosclerosis may be less so in the APO-E null mice 7 
compared with humans, in whom the most abundant lipoprotein particle is LDL. 8 
The APO-E protein is multi-functional, with roles in inflammation, oxidation, 9 
reverse cholesterol transport by macrophages, and smooth muscle proliferation 10 
and migration (Emini Veseli et al., 2017; von Scheidt et al., 2017). It is 11 
conceivable that these additional functions might affect atherosclerotic plaque 12 
development in the APO-E null mice, independent of plasma lipid levels. A further 13 
limitation of the APO-E null, diet-induced atherosclerosis model is the enhanced 14 
stability of atherosclerotic plaque. Plaque rupture and thrombosis is relatively 15 
infrequent in this model when compared with humans (Smith and Breslow, 1997; 16 
Emini Veseli et al., 2017). Animal models of mechanically induced 17 
atherosclerosis tend to induce the formation of plaque which more closely 18 
resembles human plaque in terms of morphology and stability (Emini Veseli et 19 
al., 2017). Future work may include a comparison of LOX-1 expression in plaque 20 
derived by these different methods. 21 
NIH is an inflammatory process which is unique from atherosclerosis. It remains 22 
an important aspect of atherosclerosis research, as it manifests as a complicating 23 
secondary event following vascular injury sustained from invasive treatments 24 
such as angioplasty or open surgery. Atherosclerosis and NIH do share some 25 
common features. Both are accelerated by oxidative stress; involve the 26 
chemotaxis of immune cells and release of cytokines; and lead to the migration 27 
and proliferation of VSMCs in from the media to the sub-intimal space (Hinagata 28 
et al., 2006). Evidence of a role for LOX-1 in NIH originates from experimental 29 
animal models of vascular injury. A rat model of carotid artery balloon injury found 30 
that mice treated with anti-LOX-1 antibody formed significantly less NIH 14 days 31 
post injury (Hinagata et al., 2006). The authors also examined the expression of 32 
LOX-1 in VSMCs following injury and found that LOX-1 expression increased 33 
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significantly at 24 hours and peaked at 7 days’ post injury. A similar study of 1 
balloon arterial injury found that in rats pre-treated with a synthetic selective 2 
superoxide scavenger, M40401 (a manganese(II) complex with a bis(cyclo- 3 
hexylpyridine-substituted) macrocyclic ligand), LOX-1 expression, lipid oxidation 4 
and NIH were significantly reduced at 14 days post injury (Muscoli et al., 2004). 5 
Our model of NIH differs in many ways in comparison to these studies. We 6 
combined the NIH model with a dyslipidaemic model of atherosclerosis. The 7 
advantage from our model is that it may reflect more accurately on human 8 
pathology: most patients undergoing procedures which lead to NIH are 9 
chronically dyslipidaemic. The major drawback from combining the two models is 10 
the possibility that knockout of the APO-E gene may have had some effect on 11 
NIH formation. We allowed NIH to develop over 4 weeks which is double that of 12 
previously published studies. Hinagata et al. found that LOX-1 expression in 13 
VSMCs peaked at 7 days’ post-injury. If we apply this timeframe to our results, it 14 
may be that the contribution of LOX-1 knockout or inhibition in our model had 15 
begun to plateau or decline between 7 and 28 days. Ongoing changes within this 16 
period may have been driven by the expression of other known mediators such 17 
as the SR CD36, vascular endothelial growth factor, or platelet-derived growth 18 
factor, naming only a few (Yue et al., 2019; Kwon et al., 2015; Pahk et al., 2019). 19 
We found that LOX-1 knockout did lead to a significant reduction in femoral artery 20 
NIH, however treatment with LOX-1 Affimers did not. It is conceivable that the 21 
many other factors contributing to NIH drown out any small effect that partial LOX- 22 
1 inhibition with Affimers may produce. Complete ablation in LOX-1 knockout 23 
however has a more profound effect. The contribution of LOX-1 in NIH may be 24 
less than in atherosclerosis. Furthermore, the development of NIH is focal, 25 
whereas atherosclerosis is a systemic problem. The administration of LOX-1 26 
Affimer in our model was systemic. It may be necessary to administer LOX-1 27 
inhibitors locally to more effectively reduce NIH. 28 
The metabolic effects of LOX-1 ablation are important to consider as metabolic 29 
syndrome is highly prevalent in patients presenting with cardiovascular disease 30 
(Alshehri, 2010). Metabolic syndrome is characterized by dyslipidaemia, central 31 
obesity, hypertension and insulin resistance (Grundy et al., 2004). In addition to 32 
cardiovascular risk, metabolic syndrome is associated with NASH, the leading 33 
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cause of liver impairment in the developed world (Marchesini and Marzocchi, 1 
2007). The role of LOX-1 in insulin resistance and NASH remains under 2 
investigation. A cohort study of obese patients with NASH found that particular 3 
LOX-1 polymorphisms were associated with more severe liver disease and 4 
insulin resistance (Musso et al., 2011). The findings from a transgenic mouse 5 
model of obesity comparing LOX-1 null and wild type colonies suggest that the 6 
expression of LOX-1 in adipocytes is required for pro-inflammatory cytokine 7 
secretion and lipid-induced insulin resistance. An ex-vivo model of NASH using 8 
harvested and cultured hepatic stellate cells and Kupffer cells from wild type rats 9 
also suggests an association between LOX-1 expression, dyslipidaemia and the 10 
triggering of hepatic fibrogenesis (Lu et al., 1999). We found that LOX-1 ablation 11 
was protective against obesity and diet induced insulin resistance. Prior to 12 
feeding with WD, APO-E null and APO-E/LOX-1 null mice were a similar weight 13 
and produced similar results in both glucose and insulin tolerance tests. After 12 14 
weeks of WD, the APO-E mice gained significantly more weight and became 15 
more insulin resistant. APO-E/LOX-1 null and Affimer-treated APO-E null mice 16 
maintained similar glycaemic homeostatic profiles. These findings support the 17 
understanding that LOX-1 expression plays an important role in adipocyte insulin 18 
resistance and deposition. When we assessed the effects of LOX-1 ablation on 19 
hepatic steatosis, the results were surprising. Considering the data published 20 
linking LOX-1 to NASH, we postulated that LOX-1 ablation would ameliorate the 21 
deposition of adipocytes. In fact, LOX-1 ablation led to an increase in steatosis. 22 
We took further steps to examine diet-induced steatosis in LOX-1 null mice 23 
(without the APO-E null background) and found that this dramatically increased 24 
steatosis. We know from our measurements of atherosclerosis and NIH that LOX- 25 
1 null mice are relatively protected against diet-induced atherosclerosis, 26 
indicating that the processes linking LOX-1 to hepatic steatosis must be 27 
independent of those in atherogenesis. The results also suggest that there may 28 
be some interplay between APO-E and LOX-1, given the rise in hepatic steatosis 29 
when APO-E expression is restored. Previous work by members of the 30 
Ponnambalam laboratory (Abdul-Zani, 2017) has demonstrated that blood 31 
concentration of oxLDL increases when the LOX-1 gene is knocked out 32 
(supplementary Figure B1). Analysis of liver tissue from LOX-1 null mice found 33 
that after 12 weeks of WD, pro-inflammatory signaling was significantly increased 34 
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compared to wild type mice. The suggested underlying mechanism was 1 
increased inflammatory signaling in response to raised serum levels of oxLDL. 2 
The observed increase in hepatic steatosis in LOX-1 null mice in our study is in 3 
keeping with this theory and warrants further investigation. 4 
Taken together, the results from LOX-1 Affimer administration were promising. 5 
The administration of LOX-1 Affimers did exert significant protective effects 6 
against diet induced obesity and insulin resistance. These benefits are one 7 
advantage of systemic administration, although the biodistribution of affimers 8 
remains to be established. The obvious argument against systemic therapy with 9 
LOX-1 Affimers from our research is the potential for increased hepatic steatosis. 10 
The effect of LOX-1 Affimers on hepatic steatosis is less dramatic compared with 11 
the other groups which is unsurprising, given that one would assume more 12 
pronounced effects would arise in a model of LOX-1 knockout compared with a 13 
model of LOX-1 systemic inhibition. Further work is needed to establish whether 14 
these effects are innocuous or result in more serious side effects.  15 
Our study demonstrated that LOX-1 Affimers did reduce atherosclerosis and NIH 16 
in general, however the reductions were lower compared with APO-E/LOX-1 null 17 
mice and were not significantly significant in most experiments. We expected any 18 
reduction in atherosclerosis and NIH in the LOX-1 Affimer treated group to be 19 
less compared with the APO-E/LOX-1 null group. The trend towards an overall 20 
reduction does provide grounds for further studies, given that our study was 21 
underpowered, and aspects of the experimental protocol could be further 22 
optimized, particularly the establishment of a proven delivery method and the 23 
study of LOX-1 Affimer biodistribution. An adequately powered study would 24 
require far larger groups to detect marginal benefits and this should be strongly 25 
considered in any future projects using LOX-1 affimers. 26 
 LOX-1 Affimers were administered subcutaneously by continuous infusion over 27 
8 weeks, however the Affimers were not detectable in any harvested mouse 28 
tissues (figure 4.12). There are multiple explanations for the failure of this method 29 
to detect the Affimers, including non-specific Affimer - tissue binding, the 30 
presence of free biotin in tissues and the possibility that the serum concentration 31 
of Affimers was too low to allow detection. The short half-life of the Affimer 32 
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protein, owing to its low molecular weight, has been discussed previously as a 1 
potentially problematic in any future role in therapeutics (Tiede et al., 2017). A 2 
short half-life would indeed keep serum concentrations low and may have 3 
contributed to non-detection. Non-specific tissue-binding or multimerization of the 4 
proteins either in solution or in the serum may have led the loss of a band at 11- 5 
14 kDa. The failure to validate the delivery system and to generate information 6 
about the biodistribution of the LOX-1 Affimers is the most important drawback of 7 
this experimental model. To understand the ability of LOX-1 Affimers in any future 8 
animal model, the importance of evaluating and comparing delivery systems must 9 
not be underestimated. Studies investigating the effects of anti-LOX-1 antibodies 10 
in atherosclerosis have chosen intra-peritoneal injection rather than osmotic 11 
infusion pumps. In mouse models, intra-peritoneal injection is a widely-accepted 12 
method of drug delivery and perhaps should be more strongly considered in 13 
future work. The addition of larger proteins to Affimers, e.g. PEG-ylation to 14 

















Figure 4.13 Schematic of in vivo role for LOX-1 in lipid metabolism and 6 
atherosclerosis. LOX-1 knockout and to a lesser extent LOX-1 targeting using 7 
Affimers leads to a vascular protective effect. Metabolic effects including glucose 8 
metabolism and fat deposition were also observed. While LOX-1 knockout 9 
reduces body mass and improves glucose tolerance, there may be an increase 10 
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CHAPTER 5 1 
OVERVIEW AND CONCLUDING REMARKS 2 
 3 
5.1 Discussion 4 
LOX-1 is part of a “super-family” of SRs, many of which play key roles in 5 
atherosclerosis. There is a large body of evidence and consensus in the field that 6 
the LOX-1 protein acts by scavenging oxLDL from the circulation and promotes 7 
the development of atherosclerotic plaques. Human cohort studies have linked 8 
LOX-1 polymorphisms to cardiovascular risk, and shown that circulating sLOX-1 9 
in the blood can be a biomarker for disease states (Kume et al., 2010; Kobayashi 10 
et al., 2011; Fukui et al., 2013). Other studies which examine pro-atherogenic 11 
SRs such as SR-A and CD36 have suggested that signaling crosstalk between 12 
these membrane receptors exists and that ablation of one SR can lead to the 13 
upregulation of another. There are conflicting findings and conclusions, which 14 
may serve as an important warning when considering SRs in general as 15 
therapeutic targets. SRs are expressed by a wide range of cell-types and have 16 
been implicated in other disease processes such as neurodegenerative disease, 17 
malignancy and infection. There exists a strong potential for off-target effects, 18 
particularly if considering systemic SR inhibition. 19 
 20 
5.1.1 LOX-1 and disease states 21 
The work presented in this thesis investigating the utility of LOX-1 as a 22 
therapeutic target in atherosclerosis using cell and animal models suggests that 23 
functional LOX-1 inhibition can ameliorate atherosclerosis. The results from our 24 
studies of LOX-1 ablation demonstrate advantages and potential drawbacks and 25 
limitations. LOX-1 knockout significantly reduced atherosclerosis in the aorta and 26 
femoral artery and protected against the development of insulin resistance. LOX- 27 
1 ablation had beneficial effects on the development of NIH, however these 28 
results must be interpreted in the context of a small sample size and potential for 29 
variance in the degree of vascular intimal damage incurred at the time of wire 30 
injury.  31 
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LOX-1 ablation has significant effects on liver physiology and metabolism. We 1 
demonstrated that the hepatic steatosis phenotype increased in LOX-1 knockout 2 
when mice were fed a WD: we hypothesize based on this information and results 3 
from previous researchers (Walenbergh et al., 2013; Ho et al., 2019) that this 4 
results from increased levels of circulating oxLDL leading to increased hepatic 5 
cell inflammatory signaling and adipocyte deposition. SR crosstalk leading to the 6 
upregulation of SRs in the liver is another possibility; however, we currently have 7 
no data to support this theory. Further studies investigating the effects of SR 8 
knockout on hepatic steatosis and inflammation are warranted. Optimization of 9 
the design of any future animal model of hepatic steatosis could involve the use 10 
of LDLR null mice, as opposed to APO-E null line, given the higher levels of 11 
circulating LDL rather than VLDL. This could offer a more accurate representation 12 
of the effects of oxLDL-SR interaction. Researchers may wish to consider cryo- 13 
sectioning and immunostaining of fresh frozen liver, as this would allow the 14 
staining of adipocytes with Oil Red O and improve the ease and accuracy of 15 
analysis. Immunostaining for markers of hepatic fibrosis should also be 16 
considered. 17 
 18 
5.1.2 Affimer-based LOX-1 targeting 19 
 Affimer proteins are synthetic proteins and versatile renewable affinity reagents 20 
which have far reaching potential applications as research tools and 21 
pharmaceuticals. Anti-LOX-1 antibody administration ameliorates aortic 22 
atherosclerosis in rats, and in principle, LOX-1 Affimers have the potential to 23 
cause similar effects. Unfortunately, our results from the use of LOX-1 Affimers 24 
were inconsistent. Cellular studies demonstrated that LOX-1 Affimers 25 
convincingly inhibited oxLDL–LOX-1 binding at concentrations of 0.1-1 µg/ml. 26 
The analysis of LOX-1 Affimer binding to LOX-1 expressing live cells was less 27 
convincing. Immunofluorescence techniques using a variety of fluorescent labels 28 
more frequently yielded either negative or very low signal results, making 29 
interpretation challenging. Systemic administration of LOX-1 Affimer in a mouse 30 
model protected against obesity and insulin resistance, however such treatment 31 
exerted only a moderate benefit in atherogenesis and NIH and most of the results 32 
did not reach statistical significance. One likelihood is that methods of drug 33 
 126 
delivery and the biodistribution of LOX-1 Affimers should be assessed and 1 
improved before further work along these lines is carried out.  2 
5.2 General limitations 3 
The most important limitations of this project are the strict physiological conditions 4 
under which the effects have been measured. The tetracycline inducible cell line 5 
is not a vascular cell line and the downstream signaling effects of Affimer-LOX-1 6 
binding have not been assessed.  7 
The pattern and morphology of atherosclerotic disease in patients presenting to 8 
our clinic varies greatly from patient-to-patient due to a multitude of factors such 9 
as their lifestyle and risk factor profile, their genetic pre-disposition and their pre- 10 
existing co-morbidities. As discussed in chapter 4, our transgenic mouse model 11 
of atherosclerosis is diet-induced and does not account for some of the other 12 
major factors which promote atherosclerosis in humans, such as tobacco 13 
smoking and diabetes mellitus. The role of LOX-1 in atherosclerosis has been 14 
established using in-vitro and in-vivo models similar to those presented in this 15 
thesis and share the same limitation in this regard. Our understanding of plaque 16 
morphology and the nature of its relationship with clinical outcomes in patients is 17 
an important evolving field. We have not assessed the effects of LOX-1 ablation 18 
on plaque morphology, which is important to consider when considering the 19 
potential translation of LOX-1 affimers to clinical use.  20 
 21 
5.3 Future Perspectives 22 
Human studies have demonstrated the increased expression of LOX-1 in 23 
atherosclerotic tissues ex-vivo and the increased release of sLOX-1 in the 24 
circulation of patients presenting with acute atherosclerotic events, however 25 
targeted therapy with a LOX-1 inhibitor has not yet reached human trials. LOX-1 26 
Affimers remain in the fledgling stages of development and much work is yet to 27 
be done. Our results are encouraging as they do inhibit oxLDL-LOX-1 binding 28 
and they are safe for use in animal models of disease. Systemic administration 29 
exerted greater influence on weight gain and insulin resistance compared with 30 
atherogenesis and NIH, and perhaps novel methods of local drug delivery could 31 
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improve efficacy while minimizing unwanted side-effects. Biodistribution and the 1 
improvement of serum half-life using conjugation techniques is an important area 2 
for future development. Future studies should focus on the effects of LOX-1 3 
ablation on the development of hepatic steatosis and the potential for 4 
steatohepatitis. The role of LOX-1 in organ systems implicated in the 5 
development of insulin resistance is an interesting avenue for future research and 6 
its importance cannot be overstated, given the rising prevalence of diabetes 7 
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Figure B.1. Serum oxLDL concentrations in transgenic mice fed 12 weeks 7 
of WD. Serum oxLDL concentration was significantly raised in APO-E/LOX-1 null 8 
mice compared with APO-E null mice (p= 0.016). LOX-1 null mice maintained a 9 
high concentration of oxLDL, however this was not significantly raised compared 10 
with wild type. 11 
 12 
